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Obesity Alters Global Response to Ischemia and GLP-1 Agonism 
 
 
Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of incretin 
based therapeutics which aid in blood glucose management in Type II diabetes 
mellitus (T2DM). Recent studies have demonstrated direct cardiovascular benefits 
conferred by these agents including protection in ischemia and heart failure. 
Despite these observations, human clinical trials fail to support improvements in 
cardiovascular outcomes independent of glucose lowering effects in the T2DM 
populations. Prior data from our lab demonstrate that obesity impairs GLP-1 
associated increases in myocardial glucose uptake. However, the reasons for this 
impairment/resistance to cardiac effects of GLP-1 in the setting of obesity remain 
ill defined. This investigation tested the hypothesis that underlying differences in 
the cardiac proteome and microRNA (miR) transcriptome could contribute to 
distinct cardiac responses to ischemia and activation of GLP-1 signaling in the 
setting of obesity. 
To identify whether obesity modulated cardiac functional responses to GLP-
1 related drugs, we first examined the effects of obesity on cardiac function, miR 
transcriptome, and proteome in response to short duration ischemia-reperfusion 
(I/R). We observed divergent physiologic responses (e.g. increased diastolic 
volume and systolic pressure in lean, decreased diastolic volumes in obese) to 
regional I/R in obese vs lean hearts that were associated with significant molecular 
changes as detected by protein mass spectrometry and miR microarray. Molecular 
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changes were related to myocardial calcium handling (SERCA2a, histidine-rich 
Ca2+ binding protein), myocardial structure and function (titin), and miRs relating 
to cardiac metabolism, hypertrophy, and cell death, including miR-15, miR-30, 
miR-199a, miR-214. Importantly, these effects were modified differently by GLP-1 
agonism in lean vs obese swine. 
Additional studies investigated the functional effects of 30 days of treatment 
with the GLP-1 analogue liraglutide on a model of slowly-developing, unrelieved 
coronary ischemia. Liraglutide failed to reduce infarct size or collagen deposition. 
However, analysis of left ventricular pressure-volume relationships support that 
liraglutide improved diastolic relaxation/filling, load-dependent indices of cardiac 
function, and cardiac efficiency in response to sympathetic stimulation in obese 
swine. Taken together, these findings support that miR and proteomic differences 
underlie distinct changes in functional cardiac responses to I/R and pharmacologic 
activation of GLP-1 signaling in the setting of obesity. 
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Chapter 1: Introduction to Obesity 
An Overview of Diet Induced Obesity and Metabolic Disease in the United 
States: Causes and Epidemiology 
Obesity is reaching epidemic proportions in the United States affecting more 
than one-third of adults and approximately 20% of youth1. This simple fact is quite 
concerning as obesity is a powerful risk factor for Type-2 Diabetes Mellitus (T2DM) 
and numerous cardiovascular related diseases2-4. The rate of growth of this 
epidemic is fueled on a national level by countless cultural, social, and economic 
pressures that promote increasingly sedentary lifestyles and consumption of 
readily available calorie dense foods5. A patient meets the criteria for being 
overweight or obese if they have body mass index (BMI = mass in 
kilograms/[patient height in meters]^2) above 30. Despite the many limitations of 
using BMI as a defining characteristic of obesity, it still proves to be a useful metric 
for predicting cardiovascular and diabetes related morbidity and mortality6. It is 
important to understand increased risks associated with obesity as it predisposes 
patients to all manner of negative outcomes that can seriously impact patients and 
families, as well as significantly increase the burden (both patient load and 
financial) of health care providers, government programs and insurers. Figure 1 
allows for visualization of the overlap of prevalence of obesity with two of its most 
significant sequelae, Type II diabetes mellitus, and cardiovascular disease death. 
Type II diabetes mellitus (T2DM) is one common and significant disease on 
the continuum of metabolic disease that often begins with obesity7 (Figure  2Figure 
2). T2DM is also increasing in prevalence, occurring in over 8% of adults in the US 
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as of 2010 and projected to increase to 33% by the year 20504. According to the 
Center for Disease Control between 2003 and 2006 American adults with T2DM 
experienced 1.7 times higher rates of cardiovascular disease (CVD) related death, 
and had hospitalizations rates that were 1.8 times higher for heart attack and 1.5 
times higher for stroke than adults without diagnosed T2DM4. Worsening of the 
obesity and T2DM epidemics, create an ever growing need to counter the CVD 
associated with these impaired metabolic states. The importance of elucidating the 
effects of metabolic disease on CVD are dire as CVD kills more people than any 
other cause in the western world. In addition to having profound medical 
implications, the 2014 CDC National Diabetes Report estimated that the total cost 
of diabetes in the US was 245 billion dollars in 20124. Improved prevention and 
treatment of obesity, T2DM and their cardiovascular sequelae would greatly 
reduce national morbidity and mortality, not to mention significant cost to our 
overburdened health care system. 
Obesity and Diabetes Worsen Cardiovascular Disease Morbidity and 
mortality 
Obesity and its associated metabolic derangements (ObM) are known to 
increase prevalence, severity and death due to cardiovascular disease outcomes8-
13 (see Figure 3). Excess fat stores across the whole body produce many changes 
in normal physiology (Figure 4). These perturbations are evidenced by the 
common clinical findings (each of which are independent risk factors for 
cardiovascular events) in patients on the ObM spectrum, including: hypertension14, 
dyslipidemia, glucose intolerance, insulin resistance, elevated inflammation 
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biomarkers, and a variety of ECG changes (Table 1)15, 16. As metabolic/physiologic 
derangements progress, alterations in substrate utilization (decreased glucose 
metabolism and increased free fatty acid metabolism), inflammation, fibrosis17 and 
cell death contribute to impairments of cardiac function are believed to contribute 
to the interrelation of obesity, T2DM, cardiac dysfunction and worsened outcomes 
of CVD16.  These outcomes include increased risk and severity of myocardial 
infarction, arrhythmias, heart failure, and sudden cardiac death2, 8-12, 18-20. Despite 
the well-defined clinical observations, more investigation is needed to improve 
understanding of the processes mechanisms underlying this exacerbation of CVD. 
Because several physiologic parameters are altered (Figure 5, Figure 6), many 
molecular pathways are implicated in driving cardiac physiology away from normal 
phenotype.  
Obesity Alters Normal Cardiac Physiology: Mechanisms of Obesity-
Associated Cardiac Dysfunction 
There are many components of normal physiology that are known to be 
perturbed in the setting of obesity. As stated previously, the focus of this document 
is limited primarily to adult obesity and metabolic disease. For a discussion of 
childhood obesity and cardiovascular disease, please read the review by Tracey 
Bridger M.D 21.  The following section will provide an overview of the effects of 
ObM on hyperdynamic circulation, adrenergics, the Renin-Angiotensin-
Aldosterone System (RAAS), cardiac function, and vascular function. While not 
discussed in this document, other important factors are implicated in obese effects 
on cardiovascular physiology (hypertrophy/fibrosis17, 22-25, lipotoxicity26, 
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metabolism27/autophagy28/mitochondrial function29, epigenetics30, inflammation31, 
sleep apnea/hypoxia29) and participate in driving all of the disease processes that 
are discussed in more detial32. 
Associations of RAAS, a Hyperdynamic Circulatory State, and Hypertension 
with Aberrant Vascular and Cardiac Morphology and Function in ObM 
Significant accumulations in body fat depots (Figure 4) contribute to altered 
neuro-endocrine-immune cross talk, thereby producing a multi-system disease 
state15. ObM coincides with blood volume and endocrine changes leading to the 
activation of the RAAS and closely associated neural and endocrine changes 
contribute to increased sympathetic tone (see subsection called ‘Systemic 
Adrenergic Overdrive Potentiates Cardiovascular damage’)15. Chronic angiotensin 
II signaling has a multitude of effects. Importantly, it produces increases in 
vasoconstriction33-36 that contribute to the production of a hyperdynamic circulatory 
state (discussed in the following paragraph). Angiotensin II is also known to induce 
inflammation, vascular and cardiac remodeling, thrombosis, and plaque rupture37. 
Early/uncomplicated obesity is associated with the development of a 
“hyperdynamic” circulatory state in which blood pressure, central blood volume, 
cardiac output and tissue metabolic demand are significantly elevated relative to 
normal 31, 38, 39. Normally, increases in central blood volume should be associated 
with greater cardiac output. However, ObM associated impairments in peripheral 
vascular function (increased resistance driven in part by RAAS discussed above) 
drives significant elevations in blood pressure40. Hypertension amplifies 
deraignment independent of obesity, producing autonomic41/endocrine42 changes 
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and vascular damage43, promoting atherosclerosis34, 35, the morphologic/functional 
changes of the heart43-45, and damage to other organs including neural and 
endocrine tissues15, 31. Thus, obesity and hypertension result in redundant and 
combinatorial systemic detriment40.  
In order to adapt to the systemic changes the heart undergoes 
morphological changes including increased left ventricular diameters and mass, 
cardiac hypertrophy (eccentric and concentric)46, 47. Morphology changes coincide 
with cardiac functional changes including reduced diastolic, and occasionally 
systolic function, have been observed in obese human subjects25, 48, 49. Over time, 
further declines in function predispose patients to myocardial infarction due to 
atherosclerosis/Coronary Artery Disease (CAD), and congestive heart failure 
(Figure 5)50-52.  
Systemic Adrenergic Overdrive Potentiates Cardiovascular damage 
The historic scientific literature relating to the effect of obesity on the 
autonomic nervous system is worthy of attention as it suggests a multifaceted role 
implicating inappropriate autonomic nervous system activity as both a cause and 
effect of obesity, and concurrently provides an example of how advancements in 
technology can change generally accepted beliefs in biological science. 
Works describing the relationship between neural/hormonal perturbations 
and obesity can be traced back to the work of Babinski in 1900 and Frohlich 1901 
53. The following seven decades provided additional case studies associating 
development of obesity with pre-existing “hypothalamic impairment”53. These 
observations, when paired with advances in the understanding of endocrine 
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functions and metabolism of lipids set the framework for the studies by Young, 
Landsberg, and Bray in the 1970’s and 1980’s.  In 1977 Young and Landsberg 
provided the first observations that altering feeding patterns could alter 
catecholamine turnover in rat hearts. Bray’s scholarly works pushed the field of 
study forward, integrating of much of the historic data and proposing mechanisms 
for further study53-55. However, studies on humans were lacking.  
Work from the Pfeifer group in 1988 provided the first characterization of 
autonomic function in several organ systems of 56 “healthy” humans (25-36 year 
old males) across a spectrum of body compositions (as measured by body fat  
percentage  2-46%)56. They found organ dependent changes in autonomic indices 
dependent on body fat percent. In the heart they found weak correlations of body 
fat percent with heart rate (r=0.3) and r-r interval (r= -0.3 after propranolol) which 
they interpreted as a decrease in overall autonomic activity in the heart. Through 
the 1980s and early 1990s, physiologists ascribed to the belief that reductions 
sympathetic tone was mediating obese changes55, 57. In 1992 a review by Young 
et al. demonstrated that literature was highly variable relating to measurements of 
plasma and urine catecholamine measurements in relation to body weight58. This 
variability arose from the use of indirect and insensitive measures of sympathetic 
activity through use of plasma and urine norepinephrine concentrations59 which 
could be overcome by use of microneurographic techniques60. In 1994, a study by 
Scherrer et al. provided strong evidence that, despite variable plasma 
norepinephrine concentrations in lean and obese humans, obesity (BMI >27) was 
associated with nearly twofold higher rates of sympathetic discharge to skeletal 
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muscle compared to lean subjects61. This hyperactivity in sympathetic nerve 
activation was reproduced by Grassi et al. in 199562. Nearly ten years later, ObM 
related sympathetic predominance in the heart began to dominate relevant 
literature63-65.  
Contrary to the early studies, it is now widely accepted that persons ObM 
exhibit heightened sympathetic tone systemically and in the heart. As discussed 
previously, multiple concurrently and interrelatedly changing factors contribute to 
change in autonomic stimulation and are thought to mutually impact a variety of 
systemic and cardiovascular systems contributing to disease progression66-69. 
Further research is needed to understand the clinical implications of non-diabetic 
obesity with respect to modulating development of cardiovascular disease and 
response to therapeutic interventions.  
Ischemic Damage in the Obese, Non-Diabetic Heart is Understudied 
Over time, these underlying changes in physiology are thought to contribute 
to augmented cardiac filling pressures, impairment of contractile function, left 
ventricular hypertrophy, left ventricular diastolic dysfunction, and diminished β-
adrenoceptor responsiveness (despite heightened sympathetic neural tone)41, 63, 
67. These changes may ultimately drive the development of the obesity 
cardiomyopathy 16, 46. In contrast to the extensive research in diabetic hearts, 
where we know diabetic individuals experience worsened outcomes to acute 
myocardial infarction70-72, coronary angioplasty 70 and coronary artery bypass 
grafting73-75, relatively little is known about the effects of (non-diabetic) obesity on 
susceptibility of the heart to ischemic damage. Experimental studies have 
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documented both impairment76 and improvement77-79 of functional recovery and 
infarct size development in response to ischemia-reperfusion injury in animal 
models of obesity79. Additional basic and clinical studies are needed to better 
understand the effects of obesity on cardiac function, on ischemia susceptibility, 
and altered pharmacologic responses.  
Cardiac Response to Ischemia 
As obligate aerobes, human cells are fundamentally incompatible with 
ischemia. Cessation of blood flow prevents delivery of nutrients and oxygen, while 
preventing the removal of cellular waste products. The mechanisms through which 
this leads to cell death begin in the mitochondria80, 81. As oxygen is unavailable, 
oxidative phosphorylation cannot proceed. Hydrogen ions accumulate in the inner 
mitochondrial matrix depolarizing the mitochondrial membrane. ATP depletion 
occurs as the cell relies on anaerobic glycolysis. Eventually ATP drops to a 
concentration in which the F1/F0 ATPase running in reverse (consuming ATP 
instead of producing it). Improper maintenance of cellular ion pump function (H+, 
Na+, Ca2+)80-82.  Improper ion gradients conclude with the elevation of cytoplasmic 
calcium, and eventual cell death83, 84. As in every other cell, in the cardiomyocytes 
(and other muscle cells) the lack of ATP necessary for proper ion pump function 
produces breakdown of normal calcium handling, however due to dependence of 
contractile function on calcium handling, ischemia has significant effects on cardiac 
rhythmicity and function. 
Minimizing damage in tissue with ischemia is dependent on expedient 
restoration of blood flow. The shorter the duration of ischemia the less damage will 
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occur83. Unfortunately, damage associated with ischemic events is not limited to 
injury resulting from ischemia.  When blood flow is restored to an ischemic tissue 
a seemingly paradoxical form of damage occurs called “reperfusion injury.”  
Reperfusion injury is mediated by biochemical pathways that result in arrhythmias, 
myocardial stunning, and microvascular obstruction85. These pathways (including 
oxidative stress86, intracellular calcium overload87, 88, mitochondrial permeability 
transition pore (MPTP) function89-92, and inflammation93-96), will not be discussed 
in detail, however citations for further reading are supplied. 
The mechanism of ischemic cell death and subsequent infarction 
development significantly overlap with cellular processes modified in obesity97. For 
example, changes in calcium handling98, 99, glucose metabolism, oxidative 
phosphorylation, mitochondrial function, etc. are associated with ObM and would 
pre-exist an ischemic event 29, 31, 32. This may have significant advantageous or 
deleterious implications for cell death. However, the impact of these ObM 
associated changes in underlying cellular physiology are sparsely investigated and 
poorly understood.  
Treatment of ObM and CVD 
Many therapeutic classes are used in the treatment of ObM and are often 
used as combination therapies to simultaneously target several mechanisms of 
disease100, 101. However, the incretin therapeutics, are of particular interest as 
evidence demonstrates its effectiveness in lowering blood glucose, and 
cardioprotective effects in ischemia and heart failure102. These injectable peptides 
work to increase the availability and/or signaling capacity of Glucagon-like Peptide 
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1 (GLP-1). The drug class has garnered much attention as it holds potential to 
disrupt both ObM and CVD, thereby significantly reducing two of the top sources 
of morbidity and mortality in the United States. 
GLP-1 Overview of Endogenous Action and Implementation as a T2DM 
Therapeutic 
Glucagon-like peptide-1 (GLP-1), is endogenously produced in intestinal L-
cells, and released in response to nutrient delivery to the small intestine. GLP-1 is 
a physiologically important hormone involved in glucose homeostasis by 
stimulating insulin and inhibiting glucagon secretion 103-105.  GLP-1 action is thought 
to exert its effect predominantly by binding of full-length GLP-1 (i.e. GLP-1 (7-36)) 
to its canonical receptor GLP-1R 106.  As a result, GLP-1 (7-36) gained interest as 
a potential therapeutic for patients with impaired glucose tolerance 107, 108. In the 
circulation, the ubiquitously expressed protease - dipeptidyl-peptidase IV (DPP-4) 
- rapidly cleaves (in minutes) circulating GLP-1 (7-36) to GLP-1 (9-36) 109.  The 
GLP-1 cleavage products likely do not activate the GLP-1R and is inactive as an 
insulinotropic agent (though this is debated) 110. Analogues of GLP-1 resistant to 
DPP-4 cleavage (e.g. exendin-4, exenatide, liraglutide) have been developed and 
are used successfully for blood glucose management 108.   
Early studies suggested that GLP-1 had cardiovascular effects as 
evidenced by increased arterial pressure in mice and cows111-113.  Further 
investigation revealed that GLP-1 modulates myocardial substrate selection and 
that GLP-1-based agents (GLP-1 fragments, GLP-1 mimetics, DPP-4 inhibitors) 
reduce myocardial ischemia/reperfusion injury and decrease severity of other 
  11 
cardiac disease (see Figure 7) 110, 114-120.  Notably, these protective effects were 
found to be independent of the glucoregulatory actions of GLP-1 and GLP-1 
mimetics 110.  
The use of incretins in prediabetic and type II diabetic patients in the 
management of their disease increased in part due to the reported cardioprotective 
benefits. However, postmarketing surveillance soon revealed that while GLP-1 
drugs were not associated with increased risk of CVD121, there appeared to be no 
reduction of CVD independent of blood glucose lowering effects122. Further 
findings revealed model-dependent discrepancies in GLP-1 benefit conferred by 
GLP-1 mimetics102. Many molecular studies have attempted to identify specific 
pathways responsible for mediating the cardiac effects of GLP1102. However, these 
studies reveal inconsistencies and are largely limited to investigations of 
promiscuous pathways (P38 MAPK, PKA, RTK etc.)102.  A perfect illustration is that 
dependent on species (though intra-species expression differences are also 
reported), experimental design and other factors (e.g. historic lack of anti-body 
specificity), there even disagreements relating even to the cardiac localization of 
the classic GLP-1 receptor102. In fact, there is evidence suggesting that there are 
unknown receptors, independent of the known GLP-1 receptor102, 123. Additionally, 
few studies have explored how GLP-1 treatment alters factors impacting protein 
expression including transcription factor expression, epigenetics, and microRNAs. 
Despite all of the molecular inconsistencies surrounding the cardiac GLP-1 
receptor(s) and its action, one important and addressable gap exists - much of the 
research demonstrating cardioprotective effects was generated in organisms that 
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lacked the common underlying disease phenotypes in patients receiving GLP-1 
therapeutics, namely obesity and metabolic disease.  
Work in our laboratory lead by Dr. Steven Moberly, provided the seminal 
observation that T2DM in obese humans impairs the GLP-1 mediated increases in 
glucose uptake that were observed in their lean counterparts (see Figure 8)124. 
Other laboratories have found additional evidence supporting obesity induced 
differences in cardio-metabolic response to GLP-1 mimetics124-126. However, 
studies investigating whether this differential response 1) extends to cardiac 
function, and 2) contributes to differential cardioprotective potential of GLP-1 drugs 
in CVD in obese vs. lean humans are lacking. 
GLP-1 Effects on Cardiac Function 
The current body of literature evaluating GLP-1 effects on cardiac function 
support that GLP-1 action is likely related to increases in diastolic filling (i.e. Frank-
Starling effect) rather than to increases in inotropy/contractility127-129. Interestingly, 
the results of these studies suggest that the cardiac effects of GLP-1 present in 
the setting of underlying stress/disease (e.g. myocardial ischemia, or heart failure).  
Human studies evaluating the cardiac functional effects of incretin drugs 
have used load-dependent techniques. As a result, statements relating GLP-1 
related effects on cardiac contractility/function made by the authors of these 
papers must be adequately interpreted as volume dependent actions of GLP-1. 
When added to background therapy for 72 hours in patients with acute myocardial 
infarction with ejection fraction (EF) <40%, GLP-1 significantly improved ejection 
fraction and wall motion 116.  In patients with class III/IV heart failure, improvements 
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in ejection fraction were reported with longer courses of therapy (5 weeks), but 
effects on ejection fraction were not observed in otherwise healthy control subjects 
130.  In a human model of acute ischemic dysfunction resulting from a 1 minute 
coronary occlusion, Read et al. examined effects of GLP-1 therapies using real 
time pressure-volume analyses and demonstrated that GLP-1 improved LV 
systolic (EF, SV, dP/dt; where dP/dt is a load dependent measure) and diastolic 
function (tau) during a 30 minute reperfusion period 131.  GLP-1 infusion also 
increased load-dependent measures of contractility (+dP/dt) and improved 
relaxation (tau) and cardiac function (EF and SV) 131.However, this study fell short 
of directly assessing end systolic pressure volume relationships, which would have 
provided load independent measures of cardiac contractility/function.  
While there is evidence supporting the ability of GLP-1 to enhance cardiac 
performance, in the setting of both ischemia and heart failure, the existing body of 
literature (due to use of load-dependent measures) is not able to explain the 
physiologic mechanisms underlying effects of GLP-1.  Lastly, inconsistencies in 
data resulting from species and metabolic differences further complicate our 
understanding. Elucidation of GLP-1 physiology and molecular action in obesity is 
needed to ensure patients receiving GLP-1 based therapies obtain 
cardioprotective benefits.  Thus, systematic study and complete evaluation of the 
effects of obesity on GLP-1 based therapies will allow us to use them more 
effectively. 
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Discovery of Mechanisms relating ObM to CVD and GLP-1 Effect 
Mass Spectrometry History 
Mass spectrometry is a technique which allows for identification of 
molecules based on mass to charge ratios. The technology leading to mass 
spectrometry arose from early experiments on anode ray tubes by Eugen 
Goldstein in 1886. Experiments by Wilhelm Wien found that strong electric or 
magnetic fields could deflect these rays of positively charged ions. In 1899 Wien 
constructed a device with parallel electric and magnetic fields that could separate 
the rays according to their charge-to-mass ratio discovering that different gasses 
had different charge to mass ratios. This work was expanded on by J.J Thomson 
who produced a mass spectrograph. In 1908 Wien used this technology and 
discovered that atoms of a single element could have different masses, what we 
now know of as isotopes. From 1918-1922 accuracy and resolution of mass 
spectrometers was improved by Arthur Dempster and F.W Aston. Increasingly 
complex mass spectrographs with ion traps developed by Hans Dehmelt and 
Wolfgang Paul in the 1950s allowed for the eventual application of mass 
spectrometry to amino acids by Carl-Ove Andersson in 1958.  However, analysis 
of peptides was still not feasible due to the large relative mass and complixity of 
the biomolecules. In 1968 Keith R. Jennings pioneered work that created collision-
induced dissociation which would lead to the tandem mass spectrometry 
techniques still used in peptide analysis to this day. In the late 1980s Joh Bennett 
Fenn, Koichi Tanka, Franz Hillenkamp and Michael Karas made major 
advancements in the ionization of biological macromolecules (including proteins) 
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yielding an early version of tandem mass spectrometry (MS/MS) techniques. 
Innovation has continued in the field, allowing complex proteins and their post-
translational modifications to be analyzed with increasing sensitivity. Many 
variations of protein mass spectrometry exist, each utilizing a different combination 
of separation techniques (HPLC, electrophoresis, etc.), dissociation and ionization 
methods, and mass analyzers to accomplish varying goals132-135. 
Mass spectrometry techniques allow for quantification of protein (see the 
review by Rodriguez et al.136 for additional information regarding label-free 
quantification methodology), sequencing of proteins, and evaluation of post-
translational modifications134-143. Mass spectrometry techniques have 
revolutionized exploration of protein biology by both providing anti-body 
independent quantification to analyze both targeted proteins (hypothesis driven) 
and whole proteomes (discovery). However, this level of detail comes at a 
significant financial cost and requires specialized skillsets and machinery. 
Additionally, proteomic analysis using these techniques are limited by several 
factors that can produce altered findings including: method of protein purification, 
difficulties detecting low abundance proteins (signal to noise), choice of label-free 
quantification methodology, and known protein database used for interpreting 
spectral results. Despite these limitations, protein mass spectrometry is a powerful 
tool for antibody independent, unbiased discovery of molecular changes 
associated with pathology and pharmacology144.  
Whole proteome analyses have previously been utilized to demonstrate 
obesity-specific changes in abundance and phosphorylation of proteins related to 
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ion transport, mitochondrial metabolism, antioxidant function and cardiac 
contractile function 132, 145-148. Missing are studies exploring obesity-specific 
proteomic changes in response to cardiac I/R (though studies exist for I/R only149-
152).  
MicroRNAs in the Obese Heart 
 The manuscripts describing the first known microRNA (miR) were 
published in 1993 by collaborating groups of researchers at Harvard University. 
Ambros, Lee, and Feinbaum found that the lin-4 gene did not produce a protein, 
but instead produced a pair of small, non-coding RNAs. Together with the Ruvkun 
lab, also at Harvard, they observed that the smaller of the two transcripts, only 22 
nucleotides long, was complementary to multiple sites in the 3’-untranslated region 
(UTR) of the lin-14 transcript and related to its posttranscriptional regulation153. 
Since these first observations, a large body of literature has emerged relating to 
this ancient family of small ribonucleoic acids.  In mammalian cells they primarily 
function as small post-transcriptional inhibitors of gene regulation by binding to 
complementary regions in the UTR of other RNA messages. MiR binding leads to 
the degradation and or sequestration of mRNA transcripts (for more information 
on the biogenesis and action of miRs please see the following reviews154, 155). 
Many miRs have predicted binding sites in the UTR of well over a thousand 
genes found within the human genome156. The ability for changes in miR 
abundance to impact multiple processes within a cell contribute to their power as 
regulators of cellular physiology. Since their discovery, screening for miRs using 
microarrays and RNA sequencing has produced observations linking changes in 
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miR expression to a variety of pathologic responses ranging from cancers/genetic 
diseases157, ischemic response158-160, cardiovascular161 and metabolic disease162-
169. Importantly, it soon became apparent that modulating miR levels could alter 
the course of various pathophysiologies170, 171. In response, several techniques 
arose that facilitate modulation of miRs using both viral vectors (allows for up and 
downregulation) and direct suppression using anti-miRs (aka stabilized antigomirs, 
which allow reduction of miR levels in a method similar to RNA interference)170, 172.  
These technologies have been applied in a number of cardiac studies and 
have found differential regulation of key miRs in various heart diseases, and that 
both reduction and increases in severity of pathologies are possible by altering 
levels of individual miRs (see Table 2 as well as the very exhaustive review by 
Bostjancic and Glavac160 for more details). While these studies illustrate the 
context specific involvement of miRs in physiology and disease, many of these 
studies reveal weaknesses that appear to be pervasive in miR research, including: 
the use of models lacking underlying disease phenotypes, single miR-single target 
assumptions, and limitation to rodent models (likely due to cost of miR modulation). 
The result is a body of literature with contradictory findings (dependent on 
species/model, experimental design - temporal factors impacting tissue sampling 
and degree of disease progression). Some groups have begun to fill this gap in 
knowledge with human studies that have provided a much more complex picture 
of miR biology than previously imagined (and still not properly acknowledged or 
appreciated by the majority of researchers within the miR field). Human studies 
have provided the valuable observations that in addition to underlying disease 
  18 
state, many common therapeutics can change the expression of various miRs173. 
Therapeutic modulation of miR expression is pathologic states has also been 
recorded in mice174. This observation has significant implications for the attempted 
application of miR modulation to clinical medicine. This is especially important with 
regards to the medication dependent clinical management of cardiovascular 
disease and ObM (where patients can easily be taking several prescribed 
medications). Further studies assessing the impact of underlying obesity on 
responses to pathology and therapeutics are needed to provide more clinically 
relevant contexts for miR research. 
Summary and Specific Aims  
While ample clinical data supports the greater risk of development and 
severity of cardiovascular disease due to obesity, associated changes in cardiac 
responses to pathologic and pharmacologic stimuli are poorly understood with 
regards to both physiology/function and molecular expression. Prior work in our 
lab has revealed that ObM modulates cardiac metabolism in response to GLP-1 in 
humans124, but little is known about whether those effects extend to cardiac 
function. Several fundamental questions arise 1) does ObM alter cardiac functional 
response to ischemia/reperfusion, 2) does obesity alter cardiac functional 
responses to GLP-1 mimetics (exendin-4) at baseline and in response to I/R, 3) 
does obesity modify cardiac microRNA and protein expression to GLP-1 mimetics 
and in the setting of I/R, 4) does treatment with GLP-1 mimetics reduce infarct 
resulting from unrelieved LAD ischemia in obese swine 5) does GLP-1 produce 
cardiac functional differences in the obese ischemic heart.  
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Increasingly sensitive screening tools have created new opportunities to 
characterize the complex interplay of cellular factors that underlie changes in 
complex disease phenomena. Accordingly, the goal of this work is to elucidate 
whether obesity alters cardiac function, injury and molecular responses to GLP-1 
therapeutics in the setting of ischemia (Figure 9). We hypothesize that obesity will 
alter cardiac functional responses to GLP-1 and I/R, and furthermore, that 
underlying these differences are associated changes in miR and protein 
expression. 
Aim 1. Determine the effects of obesity on the cardiac functional 
response to ischemia/reperfusion and/or glucagon like peptide-1 (GLP-1) 
receptor activation, and screen for underlying microRNA and protein 
changes. To investigate this aim, lean and obese Ossabaw swine were given 24 
hours of intra-venous saline or exendin-4 (30 fmol/kg/min), a GLP-1 receptor 
agonist. An open chest (thoracotomy) model was used to investigate cardiac 
function at baseline and during acute ischemia-reperfusion. Myocardial biopsies 
were taken at the conclusion of the open chest procedure from both normally 
perfused and ischemia-reperfusion territory of the left ventricle. Protein and total 
RNA were isolated from the samples and used for molecular screens using mass 
spectrometry and miR microarray. 
Aim 2. Investigate the potential for GLP-1R activation to influence 
cardiac function at rest and in response to β1-adrenergic receptor (β1ADR) 
stimulation in an obese swine model of ischemic heart disease. To test this, 
ameroid constrictors were placed on the left anterior descending (LAD) artery of 
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obese Ossabaw swine to produce a slowly developing (over the course 2 weeks), 
complete/unrelieved coronary occlusion. Following ~30 days of treatment with 
either saline, or the GLP-1 mimetic liraglutide (0.015 mg/kg/day), an open-chest 
procedure was performed in which we assessed whether liraglutide augments 
sympathetic mediated increases in cardiac contractility and improve efficiency of 
obese hearts following complete coronary occlusion and regional myocardial 
infarction. Furthermore, ex vivo investigations elucidate the impact of liraglutide 
treatment on infarct development, β1ADR expression, and titin in the infarcted and 
normally perfused myocardium. 
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Figure 1. Percentage of Populations of obesity175 are mirrored by diagnoses 
of T2DM in the united states. Additionally these metabolic diseases correspond to 
an increased rate of death from cardiovascular disease 175  
Obesity – Percentage of Population - 2012 
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Figure 2. Factors promoting cardiovascular disease risk. Many factors 
contribute to, and are interrelated in, worsening cardiovascular disease risk and 
outcomes. Adapted from Rana, J.S 2007176   
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Figure 3. ObM increases likelihood of death due to cardiovascular disease13 
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Table 1. ECG Changes associated with obesity. These changes suggest 
changes to cardiac morphology and electrical system.  Modified from Porrier, P., 
et al 31  
Obesity associated ECG Changes
↑ Heart rate
↑ PR interval
↑ QRS interval
↑ or ↓ QRS voltage
↑ QTc interval
↑ QT dispersion
↑ SAECG (late potentials)
ST-T abnormalities
ST depression
Left-axis deviation
Flattening of the T wave (inferolateral 
leads)
Left atrial abnormalities
False-positive criteria for inferior 
myocardial infarction
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Figure 4. Abnormalities increasing risk of cardiovascular disease among 
overweight/obese individuals with excess visceral adipose tissue/ectopic fat. 
Abbreviations: Apo: apolipoprotein; FFA: free fatty acids; AT: adipose tissue. 
Modified from Bastien et al.15  
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Figure 5. Pathophysiology of obesity and cardiovascular disease. The 
different physiopathological mechanisms by which obesity is associated with 
cardiovascular disease are complex and are not limited to factors such as diabetes 
mellitus type 2, hypertension or dyslipidemia. Other factors with an indirect 
interaction have been described, such as subclinical inflammation, neurohormonal 
activation with increased sympathetic tone, elevated leptin and insulin 
concentrations, obstructive sleep apnea, increased free fatty acid turnover and 
intramyocardial and subepicardial fat deposition. From Lopez-Jimenez et al. 
201152  
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Figure 6. Molecular processes modulated by ObM. Image modified from 
Bugger et al. 201430  
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miRNA Indication 
Therapeutic Effect of miR 
suppression 
Organism 
Ref 
# 
miR-15 
family 
Post-MI 
remodeling 
Reduces infarct size by increasing 
the number of viable myocytes after 
ischemic injury, resulting in 
improved cardiac function 
mouse 177 
miR-15 
family 
Cardiac 
Regeneration 
Increases the number of mitotic 
cardiomyocytes 
neonatal-
mouse 
178 
miR-19 
family 
Cardiomyocyte 
hypertrophy 
Decreases markers of hypertrophic 
signaling 
neonatal rat 
cardiomyocytes
179 
miR-21 Cardiac Fibrosis 
Inhibits and reverses cardiac 
fibrosis, leading to enhanced 
cardiac function in response to 
pressure overload 
mouse 180 
miR - 23 
and 27 
retinal 
angiogenesis 
Represses neovascularization in the 
choroid in response to laser injury 
mouse 181 
miR 24 
post-MI 
remodeling 
Reduces infarct size by increasing 
capillary density, resulting in 
improved cardiac function after MI 
zebrafish 
embryos 
182 
miR-33 atherosclerosis Increases plasma HDL in mice mouse 
183, 
184 
miR-33 atherosclerosis 
Increases plasma HDL and 
decreases VLDL in non-human 
primates on a high-fat diet 
African green 
monkeys 
185 
miR-29 aneurysms 
Increases collagen expression, 
resulting in a significant reduction in 
vascular dilation and aneurysm 
progression 
mouse 
186, 
187 
miR-92a neoangiogenesis
Enhances blood vessel growth and 
functional improvement of damaged 
tissue in models of hindlimb 
ischemia and MI 
mouse 188 
miR-92a 
Ischemia 
Reperfusion 
Injury 
Reduction in infarct size and post-
ischemic loss of function (improved 
EF and LVEDP) 
swine 189 
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miR-145 
pulmonary 
hypertension 
Reduces systolic right ventricular 
pressure during pulmonary 
hypertension 
mouse 190 
miR-155 viral myocarditis 
Lowers myocardial damage and 
increases survival  in response to 
viral myocarditis 
mouse 191 
miR-
199a 
Hypoxia 
preconditioning 
Induces hypoxia preconditioning 
neonatal rat 
cardiomyocytes
192 
miR-
199b 
cardiac 
hypertrophy 
Inhibits cardiomyocyte hypertrophy 
and fibrosis, resulting in improved 
cardiac function in different models 
of heart disease 
mouse 193 
miR-
208a 
pathological 
cardiac 
remodeling 
Blocks cardiac remodeling and 
improves cardiac function and 
survival in hypertension-induced  
heart failure 
Dahl salt-
sensitive rats 
194 
miR- 
208a 
metabolic 
disease 
Reduces weight gain and improves 
glucose handling and plasma lipid 
levels in response to  a high-fat diet 
high fat fed 
mouse model 
195 
miR-320 
post-MI 
remodelling 
Reduces infarct size in response to 
ischaemic  injury 
mouse 196 
Table 2. Therapeutic Targeting of cardiovascular miRNAs: Preclinical 
rodent and large animal studies have shown that antimiR-mediated inhibition of 
specific miRNAs has therapeutic potential in different aspects of cardiovascular 
disease. HDL, high-density lipoprotein; MI, myocardial infarction; miRNA, 
microRNA; VLDL, very-low-density lipoprotein. Modified from van Rooij et al. 2012 
197 
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Figure 7. Myocardial infarct size quantification as a percentage of the area 
at risk (AAR) (A) and as a percentage of the total left ventricle (B). Phosphate-
buffered saline (PBS) n = 9; exenatide n = 9. Representative pictures after Evans 
Blue (Sigma-Aldrich) and triphenyltetrazolium chloride staining are shown in C and 
D. Blue indicates non-threatened myocardium, red indicates the non-infarcted area 
within the area at risk, and white indicates myocardial infarction. From Timmers et 
al. JACC 2008120  
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Figure 8. Representative PET image demonstrating the effect of GLP-1 on 
myocardial glucose uptake in lean human volunteers. Below are quantifications of 
PET measures showing that GLP-1 increased myocardial glucose uptake in the 
lean heart but did not affect glucose uptake in obese T2DM humans. 
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Figure 9. This figure illustrates the contributing factors in our attempt to 
define whether cardiac functional and molecular effects of GLP-1 are different in 
lean vs obese swine. Blue text denotes that dobutamine response and β1ADR 
were only assessed in aim 2/chapter2.  
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Chapter 2: Original Research - Obesity Alters Cardiac Response to Ischemia-
Reperfusion with and without the GLP-1 mimetic, Exendin-4 
Introduction 
Obesity is a complex disease state that is accompanied by a number of 
cardiac disease risk factors including hypertension and metabolic dysregulation 
(glucose intolerance, insulin resistance, dyslipidemia)198 that are associated with 
pathologic changes in the heart (ventricular hypertrophy, heart failure)22, 24, 25, 49 
and in the vasculature (atherosclerosis, microvascular dysfunction)67, 199, 200. In 
prospective clinical studies, overweight or obese individuals have increased rates 
of cardiovascular diseases 16, 46, 201, contributing to a 2-3 fold increase in overall 
mortality relative to normal weight individuals15, 31, 201-204. In addition to a direct link 
with occlusive vascular disease, obesity is strongly associated with impairment of 
systolic and diastolic function and the development of cardiac fibrosis (i.e. obesity 
cardiomyopathy) 16, 46. Together these changes contribute to an obesity-related 
increased incidence of heart failure and associated morbidity and mortality 46, 205. 
To date studies have investigated a broad set of potential contributors to 
this impaired function, such as alterations in β-adrenoceptor signaling, oxidative 
stress, lipotoxicity, epigenetic changes, and autophagy responses30, but the 
adverse effects of obesity on cardiac function remain incompletely understood. 
The recent discovery of the important regulatory effects of small non-coding 
ribonucleic acid sequences referred to as microRNAs (miRs)206 presents novel 
opportunities for discovery in this area. Limited prior investigations suggest that 
obesity induces alterations in specific cardiac miRs (miR-34b, miR-34c, miR-199b, 
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miR-210, miR-650, and miR-223) in association with altered metabolism, 
hypertrophy and heart failure207. Improvements or exacerbations of various 
cardiovascular disease states have been described following experimental 
alterations of miRs using gene therapy or pharmacologic inhibitors of miRs 
(antimiR)197, demonstrating the functional relevance of these molecules. 
Objectively, very little is known about the nature and contributions of miRs to 
cardiovascular disease in the obese heart. 
Regulatory changes ultimately exert effects by changes in the amount 
and/or activation of cellular proteins. In parallel with advances in techniques for 
miR profiling, tools for the evaluation of whole-proteome have been developed. 
Such techniques have been used to demonstrate obesity-specific changes in 
abundance and phosphorylation of proteins related to ion transport, mitochondrial 
metabolism, antioxidant function and cardiac contractile function 145-148. Missing 
are studies exploring obesity-specific proteomic changes in response to cardiac 
ischemia and with reperfusion following relief of ischemia, and no published work 
has concurrently evaluated the changes in miRs and the proteome. Evaluating 
these changes in parallel under an experimental paradigm designed to produce an 
informative physiological context can produce novel observations of previously 
unknown factors and pathways associated with obesity-specific alterations in 
cardiac function and ischemic responses. 
Recent work from our laboratory and others indicates that obesity impairs 
the effects of glucagon like peptide-1 (GLP-1) to modify the cardio-metabolic 
response to exercise and to regional myocardial ischemia 124-126. The underlying 
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mechanisms remain largely unexplained. Here we have evaluated effects of 
obesity/metabolic syndrome on the cardiac functional response to 
ischemia/reperfusion injury with and without prior exposure to GLP-1 receptor 
activation. We tested the hypothesis that these responses differ in obese animals, 
and that these differences are associated with obesity-specific alterations in the 
cardiac proteome and microRNA (miR) transcriptome. We observed distinct 
alterations of functional responses (in vivo) accompanied by obesity-related 
differences in myocardial protein and miR expression profiles, including changes 
in previously unknown factors that could contribute to the development of obesity 
cardiomyopathy. 
Methods 
Animal Models and Surgical Preparation. This protocol and use of 
animals were approved by the Indiana University School of Medicine Institutional 
Animal Care and Use Committee and were in accordance with the Guide for the 
Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996). Male 
Ossabaw swine were placed on a normal (lean; n = 10) or modified obesogenic 
diet (obese; n = 9) for 6 months beginning at 6 months of age as previously 
described 208. These group sizes are historically sufficient to demonstrate 
important physiologic differences between animals. Briefly, lean control swine 
were fed ~2,200 kcal/day of standard chow (5L80, Purina Test Diet, Richmond, IN, 
USA) containing 18% kcal from protein, 71% kcal from complex carbohydrates, 
and 11% kcal from fat. Obese swine were fed an excess ~8,000 kcal/day high 
fat/fructose, obesogenic diet containing 17 % kcal from protein, 20% kcal from 
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complex carbohydrates, 20% kcal from fructose, and 43% kcal from fat (mixture of 
lard, hydrogenated soybean oil, and hydrogenated coconut oil), and supplemented 
with 2.0% cholesterol and 0.7% sodium cholate by weight.   
Following 6 months of their respective diets, animals were anesthetized with 
isofluorane for placement of a jugular venous catheter. The degradation-resistant 
GLP-1 analogue Exendin-4 (30 fmol/kg/min; lean; n= 5, obese; n= 5) or an 
equivalent volume of saline (lean; n= 5, obese; n= 4) was then infused systemically 
through the jugular venous catheter for 24 hours via an elastomeric balloon (MILA 
International Inc, Erlanger, Kentucky; 2 mL/hr).  Immediately following this 24 hour 
infusion, swine were anesthetized with telazol (5 mg/kg, sc), ketamine (3 mg/kg, 
sc), and xylazine (2.2mg/kg, sc) cocktail IM and anesthesia maintained with 
morphine (3 mg/kg) and α-chloralose (100 mg/kg, i.v). The exendin-4 or saline 
infusion continued throughout the remaining period of the experimental protocol. 
Depth of anesthesia was monitored by observing continuous measurements of 
arterial blood pressure and heart rate as well as regular (15 minute intervals) reflex 
tests (corneal, jaw, limb withdrawal), beginning after induction of anesthesia and 
continuing throughout the experimental protocol. Prophylactic supplementation 
with chloralose was performed every 1.5 hour to maintain a level, stage 3 plane of 
anesthesia. The right femoral artery and vein were isolated and cannulated to allow 
measurement of systemic arterial pressure and venous access, respectively. Next, 
the heart was exposed by a left lateral thoracotomy. The left circumflex artery was 
isolated for placement of a perivascular flow probe and a snare occluder. A 
catheter was then placed in the great cardiac vein to enable sampling of coronary 
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venous blood from the area supplied by the left circumflex artery. A Sci-Sense 
pressure/volume admittance catheter (Transonic Technologies, London Ontario, 
Canada) was then placed directly into the left ventricle via an apical transmural 
stab and secured with a purse-string suture. The pressure-volume system requires 
input of an estimated stroke volume. This estimate was based on manufacturer’s 
recommendation of 0.9µL/g of body weight and produced baseline cardiac 
performance values consistent with those established in swine using other 
measurement modalities. Heparin was administered intravenously at a bolus dose 
of 500 U/kg to prevent clotting. All data were recorded using IOX acquisition 
software (EMKA Technologies, Falls Church VA. USA).  
Experimental Protocol. Following surgical instrumentation, swine were 
allowed to recover for ~20 min. Hemodynamic parameters (blood pressure, heart 
rate, coronary blood flow, left ventricular volume and pressure) were continuously 
monitored throughout the experimental protocol. Baseline arterial and coronary 
venous blood samples were obtained at the end of the stabilization period. Next 
the left circumflex artery was transiently occluded for 30 min with a reversible snare 
occluder. The snare was then released to allow reperfusion of the circumflex 
perfusion territory. Hemodynamic parameters were recorded and blood samples 
were obtained at the end of 30 min of coronary occlusion, and then at 60 min 
intervals following release of the occlusion (i.e. following coronary reperfusion). At 
the end of the experimental protocol, while still anesthetized, animals were 
euthanized by fibrillation (by application of a 9 volt battery placed near the apex in 
the heart) with subsequent rapid excision of the heart. The heart was reverse 
  38 
perfused with cold calcium free Krebs solution and transmural left ventricular 
biopsies were flash frozen in liquid nitrogen for protein mass spectrometry. The 
biopsies were taken from both the left anterior descending coronary artery 
perfused region (i.e. normal, non-ischemic territory) and left circumflex coronary 
artery perfused region (i.e. ischemia-reperfusion territory) taking care to avoid 
visible vasculature.  
Metabolic analysis and troponin measurements. An Instrumentation 
Laboratories automatic blood gas analyzer (GEM Premier 3000) and CO-oximeter 
(682) system was used to measure arterial and venous pH, PCO2, PO2, 
hematocrit, hemoglobin, oxygen saturation, and oxygen content. Baseline blood 
samples were also analyzed commercially (Antech Diagnostics; Fishers, Indiana) 
for measurements of insulin, triglycerides and cholesterol. Mass of left circumflex 
perfusion territory was estimated to be 20% of total heart weight, which 
approximates the “area at risk” in this study. Troponin measures were made using 
a i-STAT1, model 300-G (Abbott, Illinois, USA), using systemic blood samples 
taken at baseline prior to coronary occlusion, and 120 min following release of the 
occlusion. 
RNA isolation, quantification and micro-RNA array. Total RNA from 
myocardial core biopsies was isolated using PureLink RNA Micro Kit (Life 
Technologies) according to the manufacturer’s instructions. Total RNA was eluted 
from the column in RNase-free water and stored at -80°C. The Agilent 2100 
Bioanalyzer Small RNA kit was used by the Center for Genetics in Indiana 
University School of Medicine to assess quantity and quality of miRNA. 
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To perform the arrays, total RNA samples were labeled using the 
Genisphere FlashTag HSR kit. The labeled samples were individually hybridized 
to Affymetrix GeneChip miRNA 3.0 arrays. They were stained and washed using 
the standard miRNA protocol. Affymetrix GeneChip Command Console Software 
(AGCC) was used to scan the arrays and generate CEL files. CEL files were 
imported into Partek Genomics Suite (Partek, Inc., St. Louis, Mo). RMA (robust 
multi-array average) signals were generated for all probe sets using the RMA 
background correction, quantile normalization and summarization by Median 
Polish209. Summarized signals for each probe set were log2 transformed. These 
log-transformed signals were used for Principal Components Analysis, hierarchical 
clustering and signal histograms to determine if there were any outlier arrays. No 
outliers were detected in this analysis. Untransformed RMA signals were used for 
fold change calculations. Contrasts were calculated as required. Fold changes 
were calculated using the untransformed RMA signals. Probe sets with log2 
expression levels < 1.0 were considered very close to background. Probe sets with 
average expression levels < 1.0 were removed before the False Discovery Rate 
(FDR) was calculated using the Storey method210.  Fold change of miRs whose 
expression was significantly different (P < 0.05) from lean saline-treated normally 
perfused controls were used to generate heat maps using the NCI CIMminer tool 
(http://discover.nci.nih.gov/cimminer). Euclidean distance and average linkage 
were used to create heat maps. To produce similar scales for both heat maps 
minimum (min) and maximum (max) fold change was added to each heat map. 
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Proteome Analysis. Myocardial biopsies were transported to the Ohio 
State University Proteomics Core. Protein was extracted from transmural 
myocardial biopsies from perfused and ischemia-reperfusion regions, prepared for 
capillary-LC-nanospray-MS/MS and subsequent label free quantitation. Proteomic 
quantifications were performed in accordance with previous studies 211, 212 In brief 
mass spectrometry methodology is detailed online at the following web address: 
http://link.springer.com/article/10.1007%2Fs00395-016-0563-4. In brief, protein 
quantification and identification was accomplished using the NCBInr Other 
Mammalia Database (version 20150104, 1,412,788 sequences). A decoy 
database was also searched to determine the false discovery rate (FDR) and 
peptides were filtered according to the FDR. The significance threshold was set at 
P < 0.05. Percolator score was used to further validate the search results and the 
actual FDR was less than 1% after using percolator scores. Label-free quantitation 
was performed using the spectral count approach, in which the relative protein 
quantitation is measured by comparing the number of MS/MS spectra identified 
from the same protein in each of the multiple LC/MSMS datasets. Scaffold was 
used for quantitation analysis. The protein filter was set at 99% to ensure the false 
discovery rate is less than 1% and the peptide filter was set at 95%. 
Proteome and miR Analysis via Ingenuity Pathway Analysis. Ingenuity 
Pathway Analysis (IPA) (a Qiagen® product) was used to assist with interpretation 
and target discovery of proteome and microarray data. As IPA does not query 
porcine databases, all array and proteomics results were converted to the nearest 
bovine (protein) or human or mouse (miR) homologs. The proteomics data set was 
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used in conjunction with the miR data set for the miR Target Finder Feature. 
Proteins and miR thresholds for inclusion in IPA analyses were set for P<0.05. 
Microarray and Proteomic Database Locations. MiR microarray results 
were uploaded to GEO (accession GSE77378). Complete microarray and 
proteomics results are also provided online via springer publishing group (doi: 
10.1007/s00395-016-0563-4). 
Statistical Analyses. Data were analyzed using the SigmaPlot statistical 
package (version 11 Systat Software Inc, San Jose, CA) and SPSS (version 22 
IBM, Chicago, IL). Data are presented as mean ± standard error. Comparisons 
were assessed by two-way repeated measures ANOVA; (Factor A = treatment 
(saline/exendin-4); Factor B = condition (baseline/occlusion/reperfusion 60 min/ 
reperfusion 120 min)). When significance was established with ANOVA, Student-
Newman-Keuls posthoc testing was performed to identify pairwise differences 
between groups and conditions. For Table 3 and Table  5A comparisons were 
assessed by one way ANOVA. The troponin data (Table 4) were significantly right-
skewed, particularly for the reperfusion values; therefore the effect of reperfusion 
was assessed using the Wilcoxon signed rank test, and to evaluate effects of 
obesity and treatment on this response generalized linear mixed modeling was 
applied in parallel to the ANOVA as above, specifying a gamma distribution without 
assumptions of equal error distributions between groups in order to correctly model 
this data distribution. Statistical significance was declared when p<0.05. Statistical 
comparisons of proteomic results were performed on proteins which met Scaffold 
false discovery rate (FDR) criterion by Student’s t-test. In accordance with our 
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discovery-based approach, proteins and miRs with P < 0.05 after passing this FDR 
threshold were considered significantly different between conditions. Proteins with 
average spectral counts of zero for a group were not statistically analyzed. 
Results 
Phenotypic characteristics and hemodynamics. Phenotypic 
characteristics of swine at baseline on the day of the physiologic studies following 
diet ± exendin-4 treatment, are presented in Table 3. The excess calorie high 
fat/fructose obesogenic diet significantly increased body weight (~39%; P = 0.006) 
and cholesterol (525%; P = 0.005) relative to the lean-control diet. Obese animals 
were significantly hyperglycemic and hyperinsulinemic, fulfilling criteria for the 
metabolic syndrome. Exendin-4 for 24 hours did not produce any statistically 
significant changes in the metabolic characteristics of lean or obese swine at 
baseline, including no detectable reduction in glycemia.  
The ischemia/reperfusion protocol produced marked elevations in troponin 
I (Table 4). The reperfusion data were markedly skewed necessitating 
nonparametric analytic approaches as described in the Methods. The effect of 
reperfusion to increase troponin (P = 0.0002) did not differ between lean and obese 
animals (P = 0.09). Exendin-4 reduced troponin values overall (P = 0.004) but the 
effect to reduce reperfusion-induced increase in troponin did not achieve 
significance (P = 0.09), and this effect did not differ between lean and obese 
animals (P = 0.85). Ischemia/reperfusion produced sequential reductions in mean 
blood pressure in lean (P < 0.001) and obese (P = 0.005) swine (Table 5 and Table 
6). Administration of exendin-4 increased mean blood pressure ~30% in lean 
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swine at baseline and during ischemia/reperfusion (P = 0.06; Table 5), while 
exendin-4 had no effect on blood pressure in obese swine (P = 0.61; Table 6). 
Heart rate was elevated at baseline in exendin-4 treated lean swine relative to lean 
controls (~30%), and decreased in both treatment groups during 
ischemia/reperfusion (P = 0.02;Table 5). Exendin-4 had no effect on heart rate in 
obese swine. These data are also presented in a format that allows direct 
comparison of hemodynamics and cardiovascular function in lean versus obese 
animals in Table 7 (saline-control) and Table 8 (exendin-4). 
Cardiac function. In lean swine, ischemia/reperfusion caused progressive 
reductions in end-diastolic volume (P = 0.002), stroke volume (P < 0.001), cardiac 
output (P = 0.003) and ejection fraction (P < 0.001) (Table 5). Under baseline 
conditions, exendin-4 administration reduced ejection fraction ~35% (P = 0.03) in 
lean swine, likely related to the ~30% increase in resting heart rate in exendin-4 
vs. control-saline treated swine (Table 5). While ejection fraction declined with 
ischemia/reperfusion in obese control and exendin-4 treated swine, end-diastolic 
volume, stroke volume, and cardiac output were not significantly altered by 
ischemia/reperfusion and/or exendin-4 in obese swine (Table 6). Of note, however, 
ejection fraction and cardiac output (untreated only) were higher during 
ischemia/reperfusion in obese vs. lean swine (Table 7 and Table 8). 
Left ventricular pressure volume loops representative of average group 
responses for lean and obese swine are presented in Figure 10. In response to 
ischemia/reperfusion, lean swine exhibited reductions in end-diastolic volume, 
systolic pressure development, and stroke volume, evident by comparing 
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pressure-volume relationships for saline-treated lean swine at baseline (Figure  
10A) and following reperfusion (Figure 10B). In contrast, obese swine maintained 
pressure development and stroke volume during ischemia/reperfusion via a 
relative right-ward shift (increase in end-diastolic volume) of the pressure-volume 
relationship, observed by comparing saline-treated obese swine at baseline 
(Figure 10C) and following reperfusion (Figure 10D). In lean swine under baseline 
conditions, exendin-4 treatment increased systolic pressure development and 
decreased stroke volume (~35%) with essentially no change in diastolic filling 
(Figure 10A). However, the ~30 mmHg increase in systolic pressure in exendin-4 
treated lean swine following ischemia/reperfusion was associated with an ~25% 
increase in end-diastolic volume relative to control (Figure 10B). In obese swine, 
exendin-4 had relatively little effect on the pressure-volume relationship at baseline 
(Figure 10C), but produced a marked left-ward shift of the loop (decrease in end-
diastolic volume with similar pressure development) following 
ischemia/reperfusion (Figure 10D). Overall the effect of exendin-4 was to mitigate 
the response to ischemia/reperfusion, although these were directionally opposite 
in lean versus obese swine.  
The relationship between stroke volume and end-diastolic volume (i.e. 
Frank-Starling relationship as an index of cardiac contractility) revealed a markedly 
lower slope in obese compared to lean swine under saline-treated control 
conditions (Figure 11; P < 0.001). Exendin-4 treatment significantly reduced stroke 
volume at a given end-diastolic volume in lean animals (Figure 11A), changing the 
intercept (P < 0.001) but not the slope (P = 0.21) of the relationship. Exendin-4 
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shifted the slope (P < 0.001) of this relationship in obese animals (Figure 11B); 
however, the final slopes were not different between lean and obese exendin-4 
treated swine.  
Protein and miR Expression Patterns. We performed capillary-lc ms/ms 
proteomic and miR microarray analyses on myocardial biopsies from the ischemic 
and non-ischemic zones from the same lean and obese swine ± exendin-4 
treatment utilized for the in vivo studies described above. A complete list of all 678 
quantified proteins, and their differences by physiologic and treatment states, is 
provided in at http://link.springer.com/article/10.1007%2Fs00395-016-0563-4. 
Among all the conditions we observed significant changes in expression of 218 
proteins. These proteins were overall related to cell structure, contractile apparatus 
and calcium handling proteins, cellular metabolism and mitochondrial function. 
Figure 12 illustrates the changes in proteins related to cardiac function and calcium 
handling. An important novel observation is that obesity was associated with 
increases in multiple isoforms of the myocardial “molecular-spring” and signaling 
integrator protein, titin (Figure 12A). The abundance of titin was further elevated 
following ischemia/reperfusion in hearts from obese but not lean swine. Exendin-
4 decreased the abundance of titin in lean and obese swine, in both normally 
perfused (P = 0.02 for lean, and P < 0.001 for obese) and ischemic (P = 0.01 for 
lean, P < 0.001 for obese) tissues. In addition, the abundance of the sarcoplasmic 
reticulum ATPase SERCA2A was augmented in hearts from obese but not lean 
swine following ischemia/reperfusion (Figure 12C). This increase in SERCA2A 
abundance was mitigated by exendin-4. Obesity also altered expression of other 
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Ca2+ binding proteins including calsequestrin-2 (Figure 12B), S100A1 (Figure 
12D), and histidine rich calcium binding protein (Figure 12E). Differences in 
expression of Protein Kinase A, a key signaling protein in cardiomyocyte 
contractility, were also noted across diet and treatment conditions (Figure 12F). 
Bioinformatics analysis of changes in protein expression using Ingenuity 
Pathway Analysis (IPA) software identified a number of effects of obesity and 
exendin-4 treatment on proteins related to cell death and survival (Table 10). 
Selected cell death and apoptosis related proteins are presented in Figure 13 (pro-
apoptotic A-D, anti-apoptotic E,F). Individual proteins were identified to exhibit 
altered amounts related to ischemia (Figure 13A and Figure 13E) or exendin-4 
treatment (Figure 13B, C, D and F). However, no differences in overall expression 
patterns of these proteins were attributable to obesity and no systematic effect of 
exendin-4 was evident. 
A listing of all miRs detected by microarray, and their differences in 
expression in each sample group, are provided online 
(http://link.springer.com/article/10.1007%2Fs00395-016-0563-4). The heat maps 
shown in Figure 14 and Figure 15 illustrate that several groups of miRs are 
concordantly altered by obesity, ischemia/reperfusion and exendin-4 treatment 
(regions marked A-D on Figure 14 and A-I on Figure 15). For example, miRs 
378,423-3p, 133a-5p, 361-3p, and 423-5p (Group A in Figure 14) were all down-
regulated by ischemia/reperfusion in lean control swine whereas a different group 
of miRs (miRs 652, 143-5p, 17-3p, 26a, 24, 214, 140-star, 143-3p, 199a, and 152) 
were down-regulated by ischemia/reperfusion in obese swine (Group D, ). 
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Interestingly, exendin-4 treatment prevented the downregulation of Group A miRs 
in lean swine during ischemia/reperfusion and resulted in altered expression of a 
distinct group of miRs (Group D, Figure 14). Obesity alone resulted in decreased 
expression of miRs 378, 130b, 1307, 331-5p, 2320, 129a, 30b-3p, 30e-3p (Group 
B, Figure 15) and upregulation of miRs 497, 494, 30c, 105-1, 331-3p. Interestingly 
some of the miRs downregulated in obese hearts (Group B, Figure 15) were also 
downregulated by ischemia/reperfusion in the lean swine (e.g. Group A, Figure 14, 
miR 378, and 133a-59). Exendin-4 prevented the alterations observed in obese 
swine (Groups A and B, Figure 15), and resulted in upregulation of miRs 491, and 
146a (Group E, Figure 15) which were unchanged in all other comparisons. Obese 
exendin-4 treated hearts during ischemia/reperfusion had the greatest number of 
miR changes, with 26 of the 36 total unique to the comparison. In particular, miRs 
decreased in group H (Figure 15) (miRs 140, 122,424-star, 345-3p, 15a, 324, let 
7 a/f/g/i, 362, 151-5p/3p, 16, 126, 106a, 425-5p, 365-3p, 181-5p, 221, 28-3p, and 
199a-3p). The functional or regulatory significance of these differences is not 
currently known, but can be inferred from bioinformatics analyses that apply known 
associations between miR species and specific categories of biological function. 
Therefore the differentially expressed groups of miRs were evaluated using IPA 
software for analysis of predicted molecular and cellular function (Table  9 and 
Table 11). The most discernable finding of this analysis was that significantly more 
miRs were altered in obese relative to lean swine and that IPA identified numerous 
potential links of these miRs to known pathways of injury and disease (Table 9 and 
Table 11) 
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To determine if any of the observed changes in miR expression could 
account for alterations in protein expression that we identified from our proteomic 
analysis we used the Target Finder feature within IPA software. A summary of 
these results and other is presented in Table 11.  Eleven miRs were identified for 
which the change in their expression inversely correlated with expression of their 
predicted target proteins. These proteins were not readily categorized into a single 
functional group although they are important metabolic, structural and signaling 
molecules. 
Discussion 
Experiments in this study were designed to explore obesity-associated 
differences in myocardial function in response to ischemia/reperfusion, and how 
these responses are modified by pharmacologic treatment (i.e. with the GLP-1 
agonist exendin-4). Admittance pressure volume catheter technology, the gold 
standard measure for cardiac function 213, 214, was used in in-vivo experiments to 
provide highly-sensitive, real time measures of cardiac pressures and volumes. 
We found that obese and lean swine produced divergent physiologic responses to 
ischemia/reperfusion, and that the effects of exendin-4 treatment on 
ischemia/reperfusion were dramatically different between lean and obese swine. 
We performed unbiased analyses of changes in protein and miR expression 
associated with these differing responses as a platform for discovery of novel 
underlying molecular changes that could contribute to the observed physiologic 
effects and differences between groups. The distinctive in vivo responses to 
ischemia/reperfusion and exendin-4 were associated with informative and 
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interestingly different expression profiles of proteins and miRs, including in factors 
known to be associated with regulation of cardiac function (validating the 
approach) but also including factors not previously known to play a regulatory or 
functional role in relation to obesity. 
Obesity and cardiac function in response to ischemia/reperfusion. We 
found that obesity is associated with a number of important functional differences 
in the regulation of cardiac contractile function and systemic hemodynamics. In 
particular, under normal baseline conditions obesity tended to produce a leftward 
shift of the left ventricular pressure-volume relationship relative to lean swine 
(Figure 10). Such reductions in end-diastolic filling volumes with similar systolic 
pressure generation have been previously observed in animal models215 and in 
obese humans216. These changes are likely attributable to augmented sympathetic 
tone, which is well documented in the setting of obesity 41, 67, 217. While the 
difference in the pressure-volume relationship between the lean and obese swine 
was relatively modest at baseline, more distinct effects were noted following 
ischemia/reperfusion. These differences were not likely attributable to differing 
infarct size, as the ischemia/reperfusion-induced increase in troponin did not differ 
between lean and obese animals (Table 4). Our data demonstrate that regional 
ischemia/reperfusion produced marked reductions in indices of global contractile 
function in lean swine, namely significant reductions in arterial pressure, ejection 
fraction (Table 5), and end-diastolic volume (Figures 10 and 11). Thus, lean swine 
exhibited post-ischemic contractile dysfunction consistent with myocardial 
stunning 218. In contrast, indices of cardiac function (stroke volume, cardiac output, 
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ejection fraction) were relatively maintained throughout ischemia/reperfusion in 
obese swine and thus, were significantly higher in obese vs. lean swine (Table 5). 
This preservation of ventricular stroke volume and pressure generation is contrary 
to the presence of an obesity cardiomyopathy phenotype which one might predict 
to observe in these animals a priori 16, 198. However, further inspection of these 
data suggests that the relative preservation of ventricular function in our model of 
early obesity was accompanied by a rightward shift in the pressure-volume 
relationship (Figure 10); i.e. obese hearts can invoke a Frank-Starling mechanism 
(increase end-diastolic filling volume) to maintain cardiac output in response to an 
ischemia/reperfusion insult (Figures 10 and 11). While the lack of post-ischemic 
contractile dysfunction in obese hearts seems unexpected, it is important to 
recognize that the slope of the relationship between stroke volume and end-
diastolic volume was significantly lower in obese relative to lean swine (Figure 11); 
furthermore, such increases in blood pressure, stroke volume, and ejection fraction 
would act to augment myocardial energy demand, ventricular wall stretch, and 
exacerbate underlying ischemic injury over time 218. Prior echocardiographic 
studies in humans are in accordance with these findings and suggest that the 
cardiac effects of obesity occur over a continuum and are directly dependent on 
the degree and duration of obesity and the degree of underlying metabolic risk 
factors 26, 67, 200. 
Effects of exendin-4 on cardiac responses to ischemia/reperfusion. 
The current study is the first to describe the functional consequences of altered 
GLP-1 responses relative to cardiovascular effects of regional 
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ischemia/reperfusion in a large animal model of obesity. There is considerable 
experimental evidence supporting beneficial cardiovascular effects of treatment 
with GLP-1 based therapies. In animal models, GLP-1 therapeutics have been 
associated with increased cardioprotective capacity related to myocardial 
substrate selection, heart rate effects, blood pressure effects, reduction in 
myocardial infarct size, and improved cardiac function125. In contrast, large clinical 
trials of GLP-1 based therapies in humans with obesity and type 2 diabetes have 
failed to show the expected cardiovascular benefits to date 219, 220. Recent work 
from our laboratory suggests that cardiometabolic effects of GLP-1 are impaired in 
the setting of obesity, raising the possibility of “cardiovascular GLP-1 resistance” 
in the population being treated with these agents 124, 126, 129.  Our data demonstrate 
that the obese state produced divergent GLP-1 therapeutic responses to 
ischemia/reperfusion. Obese treated swine maintained pressure like their 
untreated counterparts, and did so despite marked reductions in end-diastolic 
volume; i.e. increases in cardiac contractility. Lean treated swine responded to 
ischemia/reperfusion with increases in pressure generation and end-diastolic 
volume (Figure 10)Error! Reference source not found., despite overall reductions 
in stroke volume at a given ventricular filling volume (Figure 11).These 
observations contribute to the growing body of experimental and clinical literature 
supporting marked differences in cardiovascular responses to GLP-1 therapeutics 
in the setting of obesity 124, 126, 219, 221.  
Proteomic and miR expression profile in obese hearts. To explore 
potential molecular changes that could contribute to the differential cardiac 
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phenotype of obese hearts, we performed proteomics and miR microarray 
analyses on myocardial biopsies from the lean and obese swine following 
completion of the in vivo ischemia/reperfusion protocols, sampling tissue from 
ischemic and non-ischemic zones. In parallel with our physiological analyses, 
protein and miR expression analyses revealed obesity-related differences, and 
differences in changes with exendin-4 treatment, in protein and miR expression. 
Of particular note we observed increased abundance of titin in the myocardium of 
obese swine under control conditions, which was mitigated with GLP-1 therapy. 
The giant protein titin plays multiple roles within the cardiomyocyte including 
providing structure in the sarcomere (binding myosin to the z-disk); contributing 
significantly to the passive and restoring force of the cardiac sarcomere; fine-tuning 
myocardial stiffness (via differential splicing of titin transcripts as well as titin 
phosphorylation); and mediating hypertrophic signaling 222, 223. It is known that 
modulating titin (via altering the predominant isoform or the phosphorylation status) 
is associated with cardiac pathophysiology 224, but little prior work has evaluated 
the role of titin in obesity-associated cardiomyopathy. Hamdani et al. found altered 
phosphorylation status of titin of in the setting of metabolic risk 225, 226. Also, 
therapeutics that increase GLP-1 signaling have been associated with alterations 
in titin phosphorylation status226. Our observations suggest a need for further 
studies to elucidate isoform switching and phosphorylation status of titin in the 
setting of obesity, exendin-4 treatment, and ischemia/reperfusion response. 
The proteomic data confirm obesity-associated differences in calcium 
handling molecules predicted by prior work (e.g. SERCA2A 98, 99, 227, 228, 
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calsequestrin 229). Importantly these data also highlight the involvement of calcium 
handling proteins not previously associated with obesity-related cardiac 
dysfunction (e.g. histidine-rich calcium binding protein). GLP-1 mimetics have 
been found to differently modulate calcium handling in vascular smooth muscle of 
swine depending on obesity 230, but, until now, have not been associated with 
direct changes in the level of calcium handling proteins in myocardium. Modulation 
of calcium handling and titin protein abundance has profound implications for 
signaling (whether by calcium as a second messenger, or titin hypertrophic 
signaling e.g. via NFAT 223), cardiac stiffness, and cardiac contractility. Taken 
together, it appears that significant insights into the cardiac effects of obesity can 
be gained from more in depth investigation of these proteins, including for example 
splice variants of titin (e.g. N2B, N2Ba, FCT)231, phosphorylation of specific titin 
residues225, 232, down-stream NFAT signaling233-235 and the interplay with altered 
calcium handling224, 236. 226. These discoveries underscore the value of the 
proteomic approach as we have applied it, in the context of a specific set of studies 
that produce physiologically relevant states. 
MicroRNAs are recognized for their widespread regulatory roles (which are 
predominantly inhibitory). These ancient systems influence multiple pathways 
concurrently, allowing for coordinated alterations in multiple components of cellular 
physiology in response to stimuli. Microarray results demonstrate that global miR 
regulation is different in obese hearts in response to ischemia/reperfusion and drug 
intervention with exendin-4. Studies investigating miR expression changes in 
pathology or therapeutic treatment in the setting of underlying metabolic 
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abnormalities are lacking. In this study, we observed different patterns of miR 
expression between lean and obese animals, and with ischemia/reperfusion injury 
with and without exendin-4 treatment. Further, the expression patterns associated 
with combinations of these conditions were themselves different from the effects 
of the individual factors (Figure 14 and Figure 15), and therefore not predictable 
based on knowledge of the effects of individual factors. We see important 
contributions in particular from a relatively small set of miRs (let 7 family, 10a, 15, 
30 family,199 family, and 214), some of which have been previously associated 
with heart disease. In mice, ischemia was found to upregulate miR 15 family 
members177, 237, 238, miR 30 family members239, and miR 214240. In contrast to our 
observations, in that study ischemia/reperfusion did not alter expression of any of 
these miRs in lean hearts. In our data in obese swine, these miRs were significantly 
downregulated during ischemia/reperfusion (while miR-30c was upregulated in 
obese normally perfused myocardium compared to lean). A prior observation of 
diminished expression of miR-199a in early ischemia in isolated porcine 
cardiomyocytes192 is also consistent with our observed tissue level changes, 
perhaps acting via increases in cardiac Hif-1α expression. Previous studies have 
demonstrated that GLP-1 mimetics induce miR expression changes in various 
non-cardiac tissues 174, 241. However, our study is the first to demonstrate GLP-1-
induced miR expression changes in myocardium, and that those effects differ 
considerably depending on obesity status. Furthermore, miR expression response 
to ischemia/reperfusion is both GLP-1 and obesity dependent. These changes in 
miRs thus mimic the different physiological changes and responses to 
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ischemia/reperfusion that occur in response to exendin-4 in lean and obese swine, 
suggesting that they may be contributing to the pathophysiological changes. 
Growing evidence suggests that GLP-1 receptor activation alters DNA 
transcription in addition to the expected direct signaling effects 174, 241, suggesting 
the potential for a relatively unexplored mechanism through which GLP-1 may 
impart direct and/or indirect effects. Further investigation into the mechanisms of 
GLP-1 mimetic-induced transcriptome changes are needed. IPA software was 
used to generate literature associated predictions of processes effected by 
changed proteins and miRs (Table 9, Table 10 and Table 11) and provide some 
context in which experimental validation of the effects of these miRs, or miR 
groups, might be further explored. Again, the value of these observations is 
primarily related to the experimental paradigm under which the tissues were 
collected, which provides a physiological context to allow interpretation of the 
differences observed.  
Limitations. Owing to the resource-intensive nature of these studies and 
some animal loss during the ischemia/reperfusion event, sample sizes were 
relatively low in this study. Nevertheless, we noted statistically significant group- 
and treatment-related differences in key physiologic end points which were 
consistent with recent data from our laboratory 124, 125, 129 and directly associated 
with marked differences in the cardiac proteome and miR transcriptome between 
lean and obese swine both at baseline and in response to ischemic injury. These 
observations therefore are not compromised on statistical power overall.  
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 Unusually for this model, the group of animals fed the obesogenic 
diet were also hyperglycemic, hyperinsulinemic, and hypertriglyceridemic, and 
furthermore they failed to lower glucose values with the 24 hour exposure to 
exendin-4. Our current data do not allow post-hoc analyses that separate obesity 
from obesity plus dysglycemia/metabolic syndrome. These factors may have 
contributed to the observed differences between groups, however, this does not 
detract from the observations of significant group differences associated with a 
high-fat, obesogenic diet. Although our experimental protocol included progressive 
reductions in venous return using a central venous balloon for gold-standard 
assessments of contractility (i.e. end-systolic pressure volume relationship 
(ESPVR)), we were unable to acquire adequate reductions in end-diastolic volume 
in a sufficient number of animals for adequate statistical analysis of cardiac 
contractility per se. 
The molecular observations we present are associative, rather than 
representing direct experimental manipulations of these systems to evaluate 
causality. This does not diminish the overall power of our hypothesis-free approach 
as a discovery platform, because we were able to make novel and unexpected 
observations, and in particular make observations about the highly integrated and 
multi-factorial changes in these systems in response to clearly described 
experimentally induced physiologic circumstances (in the same animals). These 
observations provide novel and valuable insights into the functioning of these 
systems in ischemia, and provide the first ever description of these changes in 
response to GLP-1 agonist treatment.  
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Conclusions and Implications. Taken together, these observations 
validate this discovery approach and reveal novel associations that suggest 
previously undiscovered mechanisms contributing to the effects of obesity on the 
heart and contributing to the actions of GLP-1 following ischemia/reperfusion. 
Further experimental studies will be needed to understand the causal relationships 
between transcriptome and proteome changes such as those we have observed 
and the associated changes in myocardial function.  
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Chapter 2: Tables and Figures 
 
 
 
 
 
 
 
 
 
 
Table 3. Phenotypic characteristics of lean and obese swine. 
Measurements were performed before at baseline after 24 hours Exendin-4 or 
saline infusion. Values are mean ± SE. * P ≤ 0.05 vs. lean same treatment. 
Measurements were performed after 24 hours Exendin-4 or saline infusion. 
Phenotypic characteristics of lean and obese swine 
 
Lean Saline 
n=5 
Lean Exendin-4 
n=5 
Obese Saline 
n=4 
Obese Exendin-4 
n=5 
Body Weight (kg) 75 ± 6 67 ± 8 104 ± 6* 106 ± 4* 
Heart Weight (g) 212 ± 16 194 ± 18 247 ± 9 224 ± 11 
Glucose (mmol/L) 8.6 ± 2.3 6.8 ± 1.8 13.3 ± 1.1 14.1 ± 1.9* 
Insulin (pmol/L) 73 ± 13 52 ± 11 111 ± 57 129 ± 35 
Triglycerides (mmol/L) 0.6 ± 0.1 0.5 ± 0.1 1.0 ± 0.4 0.9 ± 0.1 
Total cholesterol (mmol/L) 1.6 ± 0.4 1.4 ± 0.4 10.0 ± 3.3* 10.1 ± 2.0* 
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Table 4. Troponin measures were acquired at the end of each experimental 
time point. Due to the use of non-parametric statistics, values are expressed as 
median [range]. Reperfusion values were significantly increased compared to 
baseline (P = 0.0002). Exendin-4 significantly reduced the troponin values overall 
(P = 0.004), although the effect of exendin-4 to reduce the reperfusion-induced 
increase in troponin did not achieve significance (P = 0.09). Obese animals were 
not statistically different in these effects (P = 0.85 overall; P = 0.09 comparing 
reperfusion-induced increase between groups).  
 Lean Obese 
 Saline Exendin-4 Saline Exendin-4 
Baseline 0.30 [0.18 – 0.67] 0.37 [0.15 – 0.57] 0.35 [0.03 – 0.66] 0.10 [0.04 – 0.33]
Reperfusion 0.88 [0.39 – 17.53] 0.55 [0.28 – 0.93] 5.05 [0.27 – 15.22] 0.84 [0.41 – 4.30]
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 Saline Exendin-4 Condition Treatment Interaction 
Mean Blood Pressure (mmHg)    
Baseline     101 ± 21     131 ± 5 
P < 0.001 P = 0.06 P = 0.89 Occlusion       89 ± 23     127 ± 6† 
Reperfusion 60 min       75 ± 11     108 ± 8 
Reperfusion 120 min       63 ± 11*       91 ± 6* 
Heart Rate (beats/min)  
Baseline       87 ± 20     113 ± 4 
P = 0.02 P = 0.96 P = 0.67 Occlusion       72 ± 8       68 ± 12 
Reperfusion 60 min       83 ± 13       84 ± 8 
Reperfusion 120 min       85 ± 14       80 ± 7 
End Diastolic Volume (ml)  
Baseline       83 ± 15       82 ± 7 
P = 0.002 P = 0.34 P = 0.42 Occlusion       60 ± 8*       77 ± 7 
Reperfusion 60 min       58 ± 7*       65 ± 6 
Reperfusion 120 min       49 ± 8*       64 ± 6 
Stroke Volume (ml)  
Baseline       41 ± 10       26 ± 5 
P < 0.001 P = 0.727 P = 0.13 Occlusion       18 ± 7*       21 ± 4 
Reperfusion 60 min       12 ± 4*       14 ± 3 
Reperfusion 120 min       11 ± 3*       13 ± 4 
Cardiac Output (L/min)  
Baseline      2.2± 0.5       1.7 ± 0.5 
P = 0.003 P = 0.97 P = 0.52 Occlusion      1.2± 0.4*      1.3 ± 0.2 
Reperfusion 60 min      0.9± 0.2*      1.1 ± 0.2 
Reperfusion 120 min      0.9± 0.2*      1.0 ± 0.3 
Ejection Fraction (%)  
Baseline       47 ± 6       31 ± 4† 
P < 0.001 P = 0.40 P = 0.04 Occlusion       27 ± 8*       26 ± 3 
Reperfusion 60 min       20 ± 5*       20 ± 3* 
Reperfusion 120 min       21 ± 4*       20 ± 4* 
 
Table 5. Hemodynamics and cardiovascular measurements of lean swine.
Values are mean ± SE for lean (n = 4) and lean + exendin-4 (n = 5) swine. By two 
way repeated measures ANOVA: * = P < 0.05 vs. Baseline, same treatment; † = 
P < 0.05 vs. lean control, same condition. Condition denotes effect of sequential 
ischemia/reperfusion (baseline/occlusion/reperfusion periods), evaluated as a 
repeated measure comparison of the 4 experimental stages; Interaction tests 
whether this ischemia/reperfusion effect differs by treatment. 
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Table 6. Hemodynamics and cardiovascular measurements of obese 
swine. Values are mean ± SE for obese (n = 4) and obese + exendin-4 (n = 4) 
swine. * = P < 0.05 vs. Baseline, same treatment. The analytic approach is identical 
to that presented for Table 5.  
      
 Saline   Exendin-4 Condition Treatment Interaction
Mean Blood Pressure (mmHg)     
Baseline 99 ± 10 89 ± 5 
P = 0.005 P = 0.61 P = 0.45 Occlusion 91 ± 8 86 ± 4 
Reperfusion 60 min 85 ± 11* 86 ± 4 
Reperfusion 120 min 83 ± 8* 77 ± 6 
Heart Rate (beats/min)     
Baseline 83 ± 8 74 ± 12 
P = 0.80 P = 0.35 P = 0.28 Occlusion 90 ± 11 68 ± 8 
Reperfusion 60 min 87 ± 11 75 ± 11 
Reperfusion 120 min 86 ± 7 77 ± 10 
End Diastolic Volume (ml)     
Baseline 66 ± 8 59 ± 5 
P = 0.68 P = 0.25 P = 0.25 Occlusion 76 ± 10 65 ± 3 
Reperfusion 60 min 97 ± 32 55 ± 7 
Reperfusion 120 min 89 ± 30 48 ± 8 
Stroke Volume (ml)    
Baseline 26 ± 5 28 ± 4 
P = 0.30 P = 0.33 P = 0.43 Occlusion 32 ± 3 31 ± 4 
Reperfusion 60 min 23 ± 8 23 ± 3 
Reperfusion 120 min 28 ± 7 17 ± 4 
Cardiac Output (L/min)    
Baseline 2.1 ± 0.4 1.9 ± 0.1 
P = 0.54 P = 0.18 P = 0.72 Occlusion 2.9 ± 0.5 2.0 ± 0.2 
Reperfusion 60 min 2.9 ± 0.9 1.8 ± 0.5 
Reperfusion 120 min 2.4 ± 0.6 1.4 ± 0.5 
Ejection Fraction (%)    
Baseline 39 ± 5 46 ± 6 
P = 0.04 P = 0.32 P = 0.80 Occlusion 42 ± 3 47 ± 6 
Reperfusion 60 min 36 ± 4 41 ± 1 
Reperfusion 120 min 35 ± 3 35 ± 2 
 
  62 
 
 
 
Table 7. Hemodynamics and cardiovascular measurements of saline 
treated swine. Values are mean ± SE for lean (n = 4) and obese (n = 4) swine. By 
two way repeated measures ANOVA: * = P < 0.05 vs. Baseline, same diet; † = P 
< 0.05 vs. lean, same condition.  
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Table 8. Hemodynamics and cardiovascular measurements of EX-4 treated 
swine. Values are mean ± SE for lean+exendin (n = 5) and obese + exendin (n = 
4) swine. *= P < 0.05 vs. Baseline, same diet; † = P < 0.05 vs. lean, same condition. 
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Heat 
Map 
Effect of  Group 
IPA Associations: Molecular and Cellular 
Function 
Lean 
I/R in Lean A cell death and survival 
EX-4 in 
Lean 
B 
cellular movement 
development 
growth and proliferation 
EX-4 and 
I/R in Lean 
C 
cell-to-cell signaling and interaction 
cellular development 
cellular growth and proliferation 
cell death and survival 
cell morphology 
D N/A 
Obese 
Obesity 
A 
cell morphology  
cellular function and maintenance 
DNA replication/ recombination/repair  
cellular assembly and organization 
A + B cell death and survival 
B 
cellular compromise  
cell cycle  
cellular development  
cell-to-cell signaling and interaction  
C cell cycle  
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I/R and 
Obesity 
C + D 
cellular development  
cellular growth and proliferation 
D 
cell death and survival 
cell-to-cell signaling and interaction 
small molecule biochemistry  
Ex-4 and 
Obesity 
E 
cell-to-cell signaling and interaction 
cellular assembly and organization 
cellular compromise 
cellular movement 
cell death and survival 
EX-4, I/R 
and 
Obesity 
F 
cell-to-cell signaling and interaction 
cellular assembly and organization  
cellular function and maintenance 
F +  H cell death and survival 
H 
cell cycle 
cellular movement 
H + I cellular growth and proliferation 
F + H + I cellular development 
G N/A 
Table 9. IPA predictions of molecular and cellular functions associated with 
miR change 
  
  66 
 Table 10. Additional IPA findings based on changes in protein and miR 
data sets across each comparison.  
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Table 11. IPA predictions of molecular and cellular functions associated with 
miR changes. P-value represents a measure of the likelihood that the association 
Heat 
Map 
Effect 
of: 
Gro
up 
IPA Associations: 
Downstream Effects 
Analysis results pertinent to 
cardiovascular system 
Prediction based 
on expression 
change vs LSN 
Prediction p-
value 
miR changed 
leading to 
prediction 
Lean 
I/R in 
Lean 
A 
Apoptosis of 
cardiomyocytes 
decreased 3.97E-02 378a-3p 
Failure of heart affected 5.62E-02 423-5p 
EX-4 in 
Lean 
B N/A    
C 
Cell Viability of Heart Cells affected 1.04E-02 133a-5p 
Arrhythmogenesis affected 1.45E-03 133a-5p 
Hypoplasia of heart ventricle increased 1.56E-02 133a-5p 
EX-4 
and I/R 
in Lean 
D 
Non-insulin-dependent 
diabetes mellitus 
affected 4.77E-02 129a 
Obese 
Obesity 
A 
dilated cardiomyopathy 
Increased; 
affected 6.93E-04 
Increased 497; 
affected 30c 
disarray of muscle cells increased 1.15E-03 497 
disorganization of 
cardiomyocytes Increased 3.84E-04 497 
fibrosis of heart affected 5.76E-04 497, 30c 
B 
diabetes mellitus affected 3.42E-03 
129a, 130b, 
378a 
inflammation of organ affected 5.30E-03 
30b-3p, 130b, 
30e-3p 
non-insulin-dependent 
diabetes mellitus 
affected 5.58E-03 129a, 130b 
I/R and 
Obesity 
C 
Differentiation of muscle cell 
lines 
increased 8.73E-03 100 
D 
Fibrosis 
affected, 
decreased 
1.41E-04 
Affected 26a, 
140*, 17-3p; 
Decreased  199a 
Hypertrophy 
decreased, 
affected 
1.82E-03 
Decreased 26a, 
199a; Affected 
214 
Diabetes mellitus affected 2.34E-03 
24, 143-3p, 152, 
17-3p 
Ex-4 
and 
Obesity 
E 
Disruption of focal 
adhesions 
increased 5.82E-04 491 
EX-4, 
I/R and 
Obesity 
F 
Quantity of ventricular 
myocytes 
increased 2.91E-04 206 
Arrhythmogenesis affected 4.85E-04 206 
Ischemia of heart affected 4.46E-03 206 
G N/A    
H 
Inflammation of organ affected 1.01E-08 
106a, 126, 51-
3p, 425-5p, 365-
3p, 221, 181d-
5p, 140, 15a 
let-7i, 324-5p 
G1/S phase transition of 
fibroblast cell lines 
increased 2.27E-06 106a, 15a, let-7i 
Dilated cardiomyopathy affected 2.20E-05 
Affected 106a, 
199a-3p, let-7i; 
Decreased 15a 
I 
Polymyositis affected 5.23E-03 30e-3p 
Inflammation of Organ affected 1.97E-02 30b-3p, 30e-3p 
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between a set of genes in your dataset and a related function is due to random 
association.   
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Figure 10. Representative pressure-volume loops for lean and obese swine 
at baseline, following ischemia-reperfusion injury, in the absence and presence of 
the GLP-1 receptor agonist exendin-4.  
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Figure 11. Effects of obesity and exendin-4 on the relationship between 
stroke volume and end-diastolic volume (i.e. Frank-Starling relationship). Solid 
lines represent best fit lines for saline (circles); dashed lines are the fit lines for 
exendin-4 (triangles). Filled symbols are measurements from the baseline pre-
occlusion state; gray symbols are measurements during occlusion; and open 
symbols are measurements at 120 minutes of reperfusion. The slope of this 
relationship was significantly diminished in obese-control vs. lean-control swine (P 
< 0.0001). Exendin-4 treatment significantly reduced stroke volume at a given end-
diastolic volume in lean animals (Panel A), changing the intercept (P < 0.001) but 
not the slope (P = 0.21) of the relationship. Exendin-4 shifted the slope (P = 0.003) 
of this relationship in obese animals (Panel B); however, the final slopes were not 
different between lean and obese exendin-4 treated swine (P = 0.92). 
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 Figure 12. Effects of obesity and exendin-4 on proteins underlying 
myocardial function and calcium handling in normally perfused hearts and in 
myocardium following ischemia/reperfusion injury. Bars represent average percent 
relative to lean normally perfused value and error bars represent standard error. * 
= P<0.05 for comparison of diet within the same treatment and condition; † = 
P<0.05 for comparison of treatment within the same condition and diet; ‡ = P<0.05 
for condition within the same diet and treatment. # = P > 0.05 for comparison 
relative to Lean Perfused Untreated myocardium. Panel A shows an aggregate of 
all titin proteins identified in mass spectrometry. Comparison for panel A by 
ANOVA All other comparisons by t-test. n=3 for lean perfused saline, n=4 lean 
perfused exendin-4, n=4 obese perfused saline, n= 4 obese perfused exendin-4, 
n=4 lean ischemic saline, n= 4 lean ischemic exendin-4, n=3 obese ischemic 
saline, n=4 obese ischemic exendin-4.  
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Figure 13. Effects of obesity and exendin-4 on proteins underlying cell death 
in normally perfused hearts and in myocardium following ischemia/reperfusion 
injury. Bars represent average percent relative to lean normally perfused value and 
error bars represent standard error. * = P<0.05 for comparison of diet within the 
same treatment and condition; † = P<0.05 for comparison of treatment within the 
same condition and diet; ‡ = P<0.05 for condition within the same diet and 
treatment. # = P > 0.05 for comparison relative to Lean Perfused Untreated 
myocardium All comparisons by unpaired T-test. n= 3 for lean perfused saline, n=4 
lean perfused exendin-4, n=4 obese perfused saline, n= 4 obese perfused 
exendin-4, n=4 lean ischemic saline, n= 4 lean ischemic exendin-4, n=3 obese 
ischemic saline, n=4 obese ischemic exendin-4.  
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Figure 14. Heat map of miRs changed in lean left ventricular myocardium. 
n = 5 for all groups within comparisons. Differently regulated clusters of miRs in 
each comparison were ascribed to a group (indicated by letters A-D), based on 
common differences within comparisons. For each group the fold change and p-
values were submitted to IPA for analysis of each cluster. Results of IPA analysis 
are presented in Table 5. Rows titled “min” and “max” were added to create similar 
scales for Figures 5 and 6. LSI = Lean Saline Ischemic. LEN = Lean EX-4 Normally 
Perfused. LEI = Lean EX-4 Ischemic. LSN = Lean Saline Normally Perfused. 
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 Figure 15. Heat map of miRs changed in obese left ventricular myocardium. 
For Lean saline perfused (n = 5). n = 4 obese saline, n = 5 obese exendin-4 
ischemic and normally perfused. Differently regulated clusters of miRs in each 
comparison were ascribed to a group (indicated by letters A-I). For each group the 
fold change and p-values were submitted to IPA for analysis of each cluster. 
Results of IPA analysis are presented in Table 4. Rows titled “min” and “max” were 
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added to create similar scales for Figures 4 and 5. OSN = Obese Saline Normally 
Perfused. OSI = Obese Saline Ischemic. OEN = Obese EX-4 Normally Perfused. 
OEI = Obese exendin-4 ischemic. LSN = Lean Saline Normally Perfused 
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Chapter 3: Glucagon like peptide-1 receptor activation augments sympathetic 
mediated increases in cardiac function and improves efficiency in obese swine 
following myocardial infarction 
Introduction 
The use of glucagon like peptide-1 (GLP-1) based therapies for the 
treatment of type 2 diabetes mellitus has increased significantly since the initial 
discovery of incretin hormones in the early 1980’s 102.  While these agents 
demonstrate unequivocal efficacy in the control of blood glucose concentration, an 
emerging body of evidence indicates that these compounds also have direct 
cardiovascular benefit, including improvements in cardiac contractile function 129 
and reductions in myocardial infarct size 120.  Because obesity is associated with 
increased incidence and severity of negative cardiovascular outcomes 15, 51 these 
potential cardioprotective findings hold great therapeutic potential. However, prior 
studies of the cardiovascular effects of GLP-1 have largely been performed in 
models lacking comorbidities relevant to the at risk population. 
Recent evidence supports that GLP-1 mediated increase in myocardial 
glucose uptake are attenuated in obese swine 124 and type 2 diabetic humans 124, 
126. Our laboratory has also recently documented distinct differences in cardiac 
responses to GLP-1 receptor (GLP-1R) activation in lean vs. obese swine following 
regional ischemia-reperfusion injury 242. In particular, we found that the GLP-1R 
agonist exendin-4 augmented end-diastolic volume and systolic pressure 
generation in ischemic lean hearts while maintaining systolic pressure despite 
marked reduction in diastolic filling in obese hearts 242. Proteomic analysis of left 
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ventricular myocardial biopsies demonstrated significant obesity induced 
differences in abundance of titin, PKA, and calcium handling proteins. Interestingly, 
GLP-1 based therapeutics modulated the abundance of these proteins uniquely 
dependent on obesity status. Such divergent effects combined with the failure of 
large scale clinical trials to demonstrate cardiovascular benefit of GLP-1 based 
therapeutics 243, 244 supports the need for a better understanding of the cardiac 
effects GLP-1 in the setting of obesity and metabolic dysregulation; especially in 
the setting of complex coronary vascular disease. 
The purpose of this study was to investigate the potential for GLP-1R 
activation with the clinically employed agent, liraglutide, to influence cardiac 
function at rest and in response to β1-adrenergic receptor (β1ADR) stimulation in 
an obese swine model of ischemic heart disease. Based on the previous body of 
evidence indicating the potential for significant alterations to the cardiac proteome 
with GLP-1 based therapies 242, we hypothesized that chronic (~3-4 weeks) 
administration of the GLP-1 analogue liraglutide would demonstrate 
cardioprotective capacity in the ischemic hearts of obese animals through either 
infarct mitigation or alterations to cardiac function despite the previously 
documented absence of these effects in a more acute setting 124, 126, 245, 246. 
Additional studies were also performed to examine the impact of liraglutide 
treatment on infarct development and β1ADR expression in the infarcted and 
normally perfused myocardium. These findings provide insight into the cardiac 
effects of GLP-1 related therapeutics in a relevant animal model of slowly 
developing, unrelieved, regional myocardial ischemia. 
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Materials and Methods 
Surgical preparation and Experimental Protocol 
All experiments involving animals were approved by an Institutional Animal 
Care and Use Committee and performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 2011). Ossabaw 
Swine were placed on an obesogenic diet at approximately 6 months of age 
containing ~8,000 kcal/day high fat/fructose, 16 % kcal from protein, 41 % kcal 
from complex carbohydrates, 19 % kcal from fructose, and 43 % kcal from fat 
(mixture of lard, hydrogenated soybean oil, and hydrogenated coconut oil), and 
supplemented with 2.0 % cholesterol and 0.7 % sodium cholate by weight (KT324, 
Purina Test Diet, Richmond, IN, USA).  At ~1 year of age, animals were randomly 
assigned to either saline or liraglutide treatment groups with animals weighing 60 
± 3.6 kg.  At time of assignment to treatment group, animals were sedated with 
telazol, xylazine, and ketamine (5, 2.5, and 2.5 mg/kg, s.c.) prior to anesthesia with 
isoflurane (~1.5 - 3%).  A brief thoracotomy procedure was performed and an 
ameroid constrictor (Research Instruments Southwest) placed on the proximal 
LAD in all animals regardless of treatment group.  Animals were survived out for 
four weeks during which they received a step-up protocol of liraglutide (Week 1: 
0.005, Week 2: 0.010, Week 3: 0.015, Week 4: 0.015 mg/kg/day; s.c.) or volume 
matched saline injections (Figure 16).  At the end of the four-week treatment 
period, a terminal in vivo study was performed in each animal.  In brief, animals 
were sedated again using the cocktail detailed above and anesthesia maintained 
with morphine (3 mg/kg, i.m.) and α-chloralose (100 mg/kg, i.v.).  Catheters were 
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placed into the right femoral artery and vein for systemic hemodynamic 
measurements and administration of supplemental anesthesia, heparin and 
sodium bicarbonate respectively. A Fogarty balloon catheter (Edwards 
Lifesciences) was introduced into the left femoral vein and advanced into the 
inferior vena cava to allow for experimental reduction of venous return to the heart. 
Blood gas parameters were maintained within normal physiologic limits through 
periodic arterial blood gas analyses and appropriate adjustments to breathing rate 
and bicarbonate supplementation as necessary.  A sternotomy was performed and 
a pressure volume admittance catheter (Transonic Systems) was introduced into 
the left ventricular lumen via an apical stab and affixed with a purse string suture.  
Animals were then subjected to sympathomimetic challenge (dobutamine 0.3-
10μg/kg/min).  Following the completion of in vivo experimental protocols, hearts 
were fibrillated and excised for ex vivo studies. 
Infarct Quantification 
Immediately subsequent to the acute procedure, fibrillated hearts were 
excised and flushed with 4°C, Ca2+-free Krebs buffer (131.5 mM NaCl, 5mM KCl, 
1.2 mM NaH2PO4, 1.2 mM MgCl2, 25mM NaHCO3, 10 mM glucose) via aortic 
cannulation.  Hearts were then wrapped in plastic wrap and frozen at -20°C.  The 
following morning, hearts were removed from the freezer and sliced into 1cm thick 
sections with a P-12D slicer (National Presto Industries Inc.).  Sliced sections were 
then immersed in a 37°C, 1% w/v tetrazolium solution (0.1M NaH2PO4, 0.1M 
Na2HPO4, 10 g/L tetrazolium chloride, pH 7.4) for approximately 20 minutes with 
shaking.  Slices were then transferred to a 10% buffered formalin solution for at 
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least 24 hours.  Formalin fixed tissues were then imaged at constant focal length 
in a shadow free, controlled light environment (All-in-one smart photo light box; LS 
Pro Photo Studio) in RAW image mode with a Canon Eos Rebel SL1 (Canon) 
equipped with a Canon EF-S 18-55 mm lens. Infarct area (unstained) versus viable 
tissue (stained) was quantified on each heart slice from each animal by 2 separate 
investigators blinded to condition using ImageJ. 
Immunohistochemistry 
Biopsies from the 1cm thick heart slices were taken from both the epi- and 
endocardium of the ischemic and normally perfused regions of left ventricular 
myocardium for histological analysis. Tissues were processed into 4-5μM thick 
slices and stained using Masson’s Trichrome as well as immunohistochemistry for 
CD 163 (Abcam, ab87099, Cambridge, MA), and β1ADR (Thermo Fisher, PA5-
28808, Rockford, IL).  
The Aperio Scan Scope CS whole slide digital imaging system (360 Park 
Center Drive Vista, CA 92081) was used for imaging of histology. All slides were 
imaged at 20X magnification. Scan times ranged from 1.50 minutes to a maximum 
time of 2.25 minutes. The whole images were housed and stored in eSlide 
Manager software system and images were shot from the whole slides. Computer-
assisted morphometric analysis of digital images was performed using the included 
software of the Aperio Imaging system. The positive pixel algorithm (Aperio 
Technologies) is the only image quantitation software approved by the FDA. The 
positive pixel algorithm was used for immunostains and differentiates between blue 
and brown staining in an image. The positive pixel algorithm was modified to 
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distinguish between the blue and red colors characteristic of Masson’s Trichrome 
and was used for fibrosis staining of the myocardium.  
Trichrome Automatic Image Quantitation: The Positive Pixel Count 
Algorithm was used to quantify the amount of a specific stain present in a scanned 
slide image 247. The Positive Pixel Algorithm was altered with a hue value of 0.62, 
hue width of 0.40, and color saturation threshold of 0.005. A spectrum of color 
(range of hues and saturation) and intensity (weak, positive, and strong) were 
masked and evaluated. The algorithm counts the number and intensity‐sum in 
each intensity range, along with three additional quantities: average intensity, ratio 
of strong/total number, and average intensity of weak positive pixels. Only staining 
classified as “positive” or “strong positive” was used to calculate positivity; regions 
classified as “weak positive” were mostly cytoplasmic and background staining, 
and were not counted. The algorithm had a set of default input parameters when 
first selected; these inputs have been pre‐configured for Brown color quantification 
in the three intensity ranges (220–175, 175–100, and 100–0). Pixels which were 
stained, but did not fall into the positive‐color specification, were considered 
negative stained pixels; these pixels were counted as well, so that the fraction of 
positive to total stained pixels was determined. The ratio of the ‘Positive’ and 
‘Strong Positive’ to the total number of pixels provided the positivity percentage for 
each sample. The algorithm was applied to an image by using ImageScope. This 
program allows for the selection of an image Region of Analysis and the 
specification of input parameters. After this is completed the algorithm can be 
applied and the results can be viewed. 
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Statistical Analyses 
Data are presented as mean ± SEM and were analyzed using the Sigma 
plot statistical package (version 12 Systat Software Inc, San Jose, CA) and SPSS 
(version 22 IBM, Chicago IL). Comparisons were considered statistically significant 
when P < 0.05. The effect of treatment was assessed using two-way ANOVA.  To 
establish significance of differences at baseline, parameters were additionally 
analyzed via t-test. When significance was established with ANOVA, Student-
Newman-Keuls posthoc testing was performed to identify pairwise differences 
between groups. Multiple linear regression and analysis of covariance were used 
to compare the slopes and intercepts of the relationships between cardiac output 
vs. end-diastolic volume, and cardiac power vs. pressure volume area. Cardiac 
power was calculated as the triple product of stroke volume, aortic pressure and 
heart rate.  
Results 
Phenotypic Characteristics of Obese Swine 
Body weight on the day of ameroid placement was statistically similar in 
saline vs liraglutide treated swine (Table 12, P = 0.31). Post-treatment body weight 
was significantly lower in the liraglutide treated group as final body weights at the 
time of terminal procedure were 70 ± 6 kg in saline vs. 54 ± 3 kg in liraglutide 
treated swine (P = 0.02). Ameroid closure was complete in all animals and resulted 
in significant infarct development in both groups. However, liraglutide therapies did 
not significantly impact the overall magnitude of infarction (Saline: 15.5 ± 1.9%, n 
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= 4 vs. Liraglutide: 13.9 ± 5.4%, n = 6; P = 0.81) (Figure 17). No infarction was 
detected in sham operated swine (Data not shown).   
Effects of Liraglutide Treatment on hemodynamic and cardiac parameters 
As chronic instrumentation was limited to ameroid placement, all 
physiologic data presented were obtained during a terminal procedure (Table 13). 
Thus, data presented hereafter provide cross-sectional analyses of saline vs. 
liraglutide treated swine as opposed to longitudinal studies within each animal.  
Mean arterial pressure was similar at baseline (P = 0.87), while heart rate tended 
to be higher in liraglutide (107 ± 9 beats/min) vs. saline-treated (77 ± 13 beats/min) 
(Table 13; P = 0.07).  Additionally, key indices of cardiac function including stroke 
volume, ejection fraction, cardiac output, Tau½, and end-systolic elastance were 
unaffected by liraglutide administration under baseline conditions (Table 13). The 
volume axis intercept of the pressure volume relationship (V0) was diminished 
~50% in liraglutide (15 mL) vs. saline (33 ml) treated swine at rest, however this 
change in not achieve statistical significance (P = 0.09, Figure 18). 
To assess whether liraglutide treatment influences cardiac responses to 
β1ADR activation, swine were exposed to sympathomimetic challenge via 
systemic administration of dobutamine (0.3-10 μg/kg/min). Systolic, diastolic, and 
mean arterial pressure were not significantly affected by dobutamine in saline or 
liraglutide treated swine (Table 13). Heart rate increased dose-dependently in 
response to dobutamine in both groups and was significantly higher in liraglutide 
treated animals (P = 0.004, Table 13). These increases in heart rate were 
accompanied by reductions in stroke volume and ejection fraction values (Table 
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13), however liraglutide reduced the degree to which in these parameters were 
diminished (Figure 19) resulting from enhanced diastolic function as indicated by 
increases in dp/dtmin and Tau (Table 13). 
Both end systolic (ESV) and diastolic volumes (EDV) within the heart 
decreased in both groups with increasing dobutamine dosage. The relative degree 
of decrease was similar in both saline and liraglutide treated animals (treatment 
effect EDV P= 0.19, ESV P = 0.47).  Pressure-volume (PV) loops in Figure  18A 
and B allow for visualization of end diastolic volume and end systolic volume shifts 
and stroke volume reductions in both groups.  End diastolic volume was only 
significantly changed relative to baseline in saline treated animals at the highest 
concentration of dobutamine (P = 0.04, Table 13) and this change was not 
significant in the liraglutide group (P = 0.06, Table 13). Similarly, stroke volume 
decreased in both groups reaching significance at the 10 µg/kg/min dose (saline P 
= 0.005, liraglutide P = 0.022 Table 13). However, the magnitude of decrease in 
stroke volume over the course of the terminal procedure was reduced in liraglutide 
treated swine relative to saline (P=0.029, Figure 19A). Cardiac output values 
demonstrated a downward trend in both groups of animals with the average 
cardiac output across the range of sympathomimetic challenge being significantly 
different between treated and control animals (P = 0.02). Ejection fraction 
decreased in both saline and liraglutide treated swine during administration of 
dobutamine. Liraglutide treatment was associated with a maintenance in ejection 
fraction relative to saline at the highest dosage of dobutamine (P=0.006, Figure 
19B). 
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Overall, V0 was lower in liraglutide treated swine (P<0.001, Figure 18C) and 
increased with similar magnitude between groups in response to dobutamine 
(P=0.88, Table 14).  Cardiac relaxation, both load-dependent and independent, 
was enhanced with liraglutide as evidenced by increasingly negative dp/dt Min and 
decreases in both Tau ½ and Tau 1/e (Table 13). Load-dependent measures of 
cardiac contraction were enhanced in both groups with dose dependent increases 
in dp/dt max (maximum rate of pressure change; P=0.001) as well as significantly 
decreased contraction time (CT) relative to baseline in liraglutide groups (Table 
13).  Accordingly, the mean relaxation was different between groups across the 
range of dobutamine challenge (dp/dt min, P < 0.001; Tau 1/2, P = 0.03; Tau 1/e, P 
= 0.03).  
Load independent measures of cardiac contractility (end systolic elastance, 
aka ESPVR) were not different between both groups (Figure 18D) and did not 
change significantly due to liraglutide treatment during the duration of the 
experiment (P = 0.12, Table 14).  To account for effects of body mass on cardiac 
output, regression analysis of cardiac index (mL/min/kg body weight) vs EDV (mL) 
was performed (not shown).  Results of associated ANCOVA analyses (P<0.001) 
further support that treatment with liraglutide changes load dependent measures 
of cardiac function. Figure20 presents the relationship between cardiac output and 
EDV for both saline and liraglutide treated animals.  Despite an absence of load 
independent effects of liraglutide on contractility, liraglutide treated animals 
demonstrated a significantly greater increase in cardiac output relative to EDV with 
dobutamine challenge. 
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Relationship between liraglutide therapies and cardiac efficiency at varying 
levels of myocardial oxygen consumption 
Pressure volume area (PVA), derived from pressure volume recordings 
during reductions in preload (inferior vena cava occlusion), is linearly related to left 
ventricular myocardial oxygen consumption 248. When cardiac power (product of 
stroke volume, mean aortic pressure, and heart rate) is expressed relative to PVA 
it produces a index of cardiac efficiency (power per unit of oxygen consumed).  To 
assess whether liraglutide altered cardiac efficiency, we plotted cardiac power 
relative to PVA (Figure 21). Statistical analyses of the best fit lines support that 
liraglutide treatment increases power generation as myocardial oxygen 
consumption increases with dobutamine challenge (P=0.001 by ANCOVA) (i.e. 
cardiac efficiency is greater in liraglutide treated animals). 
Role of alteration of LV mass and collagen deposition in physiologic 
outcomes of the study 
Immediately following euthanasia the heart was removed from each animal 
and the coronary tree perfused with ice cold saline via aortic cannulation to remove 
residual blood.  The wet weight of each heart was then recorded.  Liraglutide 
therapy did not result in an alteration of total cardiac mass (saline 223 ± 18 vs. 
liraglutide 218 ± 14 g; P = 0.851) nor in heart weight/body weight ratio (saline 3.3 
± 0.4 vs. liraglutide 4.1 ± 0.2 g/kg; P = 0.396).  To further establish whether any 
physiological findings were the result of alterations to left ventricular mass, the 
cross sectional thickness of the LV free wall was determined in formalin fixed slices 
using ImageJ at a consistent anatomical location (2 centimeters distal to the 
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ameroid).  Left ventricular free wall thickness was not different based on treatment 
(saline 2.3 ± 0.1 vs. liraglutide 2.3 ± 0.1 mm; P = 0.97).  Additionally, liraglutide 
treatment did not affect collagen deposition as there were no significant differences 
in Masson’s Trichrome staining (treatment effect within the ischemic P = 0.62, and 
P = 0.60 within perfused regions). 
Immunohistochemistry of Formalin Fixed Tissues 
Immunohistochemistry (IHC) was performed on formalin fixed myocardium 
to establish whether changes in β1ADR underlie functional effects of liraglutide in 
response to sympathomimetic challenge. Liraglutide treatment was associated 
with significant reductions in β1ADR expression (Figure 22) in perfused 
myocardium (P = 0.017). Liraglutide treatment also diminished the ischemia 
induced reduction in β1ADR expression observed in saline treated myocardium (P 
= 0.001 for saline; P = 0.60 liraglutide). 
Discussion 
GLP-1 receptor activation has been implicated in cardioprotective 
phenomena observed in healthy animal models receiving recombinant GLP-1 
based therapies.  To date, little data exist to interrogate the cardioprotective 
potential of these therapies in the setting of complex heart disease. As GLP-1 
based therapies are classically employed for the purpose of glucose regulation in 
a type II diabetes mellitus (T2DM) population and T2DM is positively associated 
with overweight/obesity, assessment of the cardiovascular effects in the setting of 
obesity is crucial. In this investigation we examined the effects of GLP-1 receptor 
activation via liraglutide on cardiac function at rest and in response to β1ADR 
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stimulation in an obese swine model of slowly developing ischemic heart disease 
using ameroid occluders. This design allows for examination of infarct limiting 
capacities of GLP-1 based therapies as well as cardiac performance alterations 
resulting from GLP-1 based therapies across a range of myocardial oxygen 
consumption in a gold-standard model of myocardial infarction. 
Weight loss effects 
Regardless of the specific drug in question, GLP-1 based therapies are 
consistently associated with weight loss in the clinical setting 249, 250.  At the time 
of study initiation, animals were statistically similar in mass and notably heavier 
than age matched animals employed in previous studies (Table 12)124, 129, 251.  At 
the time of terminal procedure, animals that had been placed on liraglutide 
therapies weighed significantly less than saline treated animals.  However, there 
was no significant or apparent weight loss in either saline or liraglutide treated 
animals.  Rather, liraglutide therapies were associated with attenuated weight gain.  
Ossabaw swine typically gain between 0.06-0.10 Kg/day252-255 when maintained 
on a normal laboratory diet.  Swine in this study were maintained on the high fat 
obesogenic chow prior and subsequent to ameroid placement.  Therefore, 
significant weight gain is expected across a 30 day period.  Saline treated animals 
behaved consistent with this expectation and gained approximately 9kg in 30 days.  
By contrast, liraglutide animals gained less weight with ~1kg of weight gain across 
an identical period. Despite this significant difference in animal mass at the time of 
study, there was no difference in degree of infarction between treatment groups. 
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Infarct Size 
This study examined GLP-1 based cardioprotection in the context of a 
slowly developing, unrelieved, regional myocardial ischemia.  To accomplish this, 
an ameroid constrictor was placed around the proximal LAD during a survival 
procedure.  Ameroid constrictors are a well-established tool in the study of 
coronary artery disease in swine models.  Post-mortem analyses of ameroid 
closure through excision and examination under a dissecting microscope verified 
a 100% closure rate in all study animals; i.e. each animal experienced total 
regional ischemia of the LAD perfusion territory distal to the ameroid.  The 
consistency of closure between both animals and groups is exemplified by the 
results of tetrazolium staining of the heart which demonstrated a consistent ~15% 
infarction of the LV (Figure 17). 
The failure of chronic liraglutide therapy to mitigate the degree of 
myocardial infarction stands in contrast to work by Timmers et al. who found that 
administration of a comparable GLP-1 agonist, exenatide, reduced infarct size in 
the setting of acute ischemia reperfusion injury in otherwise healthy swine120.  
Timmers’ data are further supported by clinical studies demonstrating infarct 
lowering capacity of exenatide in patients receiving angioplasty for the treatment 
of S-T elevated myocardial infarction256-258. How then are these disparate findings 
reconciled?  The Timmers study examines a transient and relieved ischemia 
whereas this work exampins a chronic and unrelieved ischemia.  One would 
predict, a priori, that there would likely be little to no effect of compound on infarct 
size in the setting of unrelieved ischemia owing to the absence of a reperfusion 
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period, the limited endogenous collateral network in swine and the limited capacity 
for angiogenesis in swine cardiac tissue. Despite the absence of infarct mitigation, 
significant improvements in cardiac function and efficiency (discussed below) 
were demonstrated in this study and the consistency of infarct between treatment 
arms minimizes the possibility that these effects are the result of changes to viable 
myocardial mass.  
Hemodynamics 
Pressor effects of GLP-1 based drugs have been reported for over 20 years.  
This effect is particularly pronounced in rodent models which routinely report 
significant increases in mean pressure as high as 20 mmHg.  By contrast human 
studies have consistently demonstrated relatively pressor responses, reporting 
elevations of 2-3 mmHg or reductions < 3 mmHg in response to GLP-1 receptor 
agonism259-261. Additionally, the physiological status of study subjects significantly 
impacts the results or GLP-1 therapies on pressor responses.  Therefore, the 
absence of a pressor response in this study (Table 13) is consistent with the body 
of literature demonstrating variable/modest effects of GLP-1 drugs on blood 
pressure. Moreover, the stable hemodynamic profile of treated animals in this 
study is consistent with work by Lovshin et al. who found that 3 weeks of liraglutide 
treatment failed to modulate blood pressure in patients with type II diabetes 262. 
Whereas the results of this study, with regards to blood pressure, are 
confirmatory in regards to baseline measures, this study provides new insights into 
the ability of chronic GLP-1 therapies to modulate responsiveness to sympathetic 
administration of a sympathomimetic agent.  Central effects of GLP-1 therapies 
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are well established in rodents but remain more equivocal in large animal models 
and humans.  Previous work by our group identified no effect of hexamethonium 
treatment on changes to cardiac performance resulting from acute administration 
of GLP-1 (7-36) in the setting of myocardial ischemia 129.  These data further 
support an absence of sympathomimetic modulation by GLP-1 based therapies 
with regards to pressor responses in that systolic, diastolic and mean pressures 
are all consistent between treatment groups across the range of dobutamine 
challenge. 
Cardiac Function 
Similar to the pressor effects discussed above, GLP-1 mediated 
chronotropy (positive or negative) is highly variable in a species specific manner125.  
Anecdotally, tachycardia is most pronounced in those species which demonstrate 
the greatest pressor responses to GLP-1 therapies.  By contrast, meta-analyses 
of human studies report modest GLP-1 related tachycardia with increases in heart 
rate of less than 2 beats per minute 249.  The results of this study are more 
consistent with human studies in that there is a modest increase in resting heart 
rate that fails to achieve statistical significance (P = 0.205).  In response to 
sympathomimetic challenge, GLP-1 therapy resulted in a significantly higher heart 
rate across the dose response range (Table 12; P = 0.004) although the magnitude 
of change relative to baseline is consistent between groups (Table 14; P = 0.44).  
These data support a potential to modestly increase heart rate at rest although 
whether this is the result of actions on the nodal myocardium remains to be directly 
determined.  To assess the potential of peripheral dilation, indirectly, peripheral 
  92 
vascular resistance (calculated as MAP/CO) was calculated and found to not be 
different between groups minimizing the potential for peripheral dilation to be a 
contributor to tachycardic responses and supporting direct effects on the 
myocardium. 
To establish the intropic potential of GLP-1 based therapies in the setting of 
myocardial ischemia and obesity, we performed high resolution left ventricular 
pressure volume analyses wherein preload was modulated by transient blockade 
of return through the inferior vena cava with a Fogarty balloon catheter.  By 
determining the end systolic pressure volume points across a range of preload, we 
are able to assess the end systolic pressure volume relationship in a load 
independent manner.  This serves as a gold standard measure of contractility 213.  
This relationship is defined by two major characteristics.  The slope of the end 
systolic pressure volume relationship defines the end systolic elastance (Ees) and 
is the classical measure of inotropy.  Therefore, an increase in Ees would indicate 
enhanced cardiac contractility and a decrease in the slope of Ees would indicate 
decreased cardiac contractility.  The other major parameter obtained in a preload 
reduction is the volume axis intercept (V0) which is the theoretical volume at and 
below which the left ventricle no longer generates pressure.  Based on this, 
changes in V0 are often used as a measure of Starling forces in the heart as in V0 
values approaching zero, indicate force development at lower degrees of wall 
stretch. 
In this study, liraglutide was found to lower V0 significantly at baseline at low 
dobutamine concentration, indicating earlier inotropy independent (i.e. Starling) 
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force development at rest.  This finding is consistent with previous work by our 
group which found improvements in left ventricular ejection fraction and GLP-1 
mediated changes in cardiac function relating to diastolic filling (i.e. Frank-Starling 
effect Figure 20) rather than inotropy 129.  However, these observations were not 
made in obese hearts.  Findings from this study are consistent with recent 
observations by Sassoon et. al. which demonstrate increases in inotropy of obese 
hearts in the setting of ischemia reperfusion242. 
Interestingly, Ees was not enhanced with dobutamine challenge in saline 
treated animals when examined as either an absolute change or a change relative 
to baseline.  By notable contrast, liraglutide therapies preserved the ability of the 
heart to respond to adrenoreceptor activation in that there is a continuous increase 
in Ees across the range of dobutamine challenge both absolutely and relative to 
baseline. These data are further supported upon examination of the relationship 
between end diastolic volume and cardiac output (Starling Curve; Figure 20) which 
demonstrate that liraglutide treatment results in a shift of the relationship of EDV 
to CO such that at any given EDV, CO is greater in liraglutide treated animals 
relative to their saline counterparts.  Classically this relationship has been used to 
establish whether a system is demonstrating an inotropic response.   Taken 
together, these data support the ability of liraglutide therapy to preserve 
sympathetic sensitivity in the setting of myocardial ischemia and obesity.  How 
then does this preservation occur? 
Histological analyses of myocardial biopsies obtained immediately post-
mortem provide some insight into how liraglutide therapies maintain sympathetic 
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responsiveness in the heart.  Figure 21 depicts representative images of 
myocardium stained for the β-1 adrenoreceptor. Using the FDA approved 
algorithm (from Aperio), we were able to perform quantification on these biopsies. 
Relative to saline treated animals, the normally perfused myocardium of liraglutide 
treated animals exhibited lower levels of β-1 adrenoreceptor by approximately 
50%. However, whereas the ischemic territory of saline treated animals exhibited 
only 10% of the staining found in the perfused territory, liraglutide treated animals 
demonstrated no reduction in β-1 adrenoreceptor resulting from ischemia.  These 
data support an ability of liraglutide therapies to maintain β-1 adrenoreceptor levels 
despite myocardial ischemia. 
Figure 18 presents representative left ventricular pressure volume loops 
which provide visual insight into the integrated response of the heart to liraglutide 
therapies in response to dobutamine challenge. At rest, all volume and pressure 
measures are similar between saline and liraglutide treated animals including end 
diastolic volume, end systolic volume, stroke volume, cardiac output and ejection 
fraction.  Also, in addition to the previously mentioned volume independent 
measures, volume dependent measures of cardiac function including contraction 
time, relaxation time, dp/dtmax, dp/dtmin, and Tau were similar at rest.  Therefore, 
at rest, the hearts in both treatment groups are providing similar cardiac work.  
Dobutamine challenge identified varied responses in a number of indices.  With 
increasing heart rate came an accompanying and anticipated reduction in both end 
diastolic volume and end systolic volume in both groups.  The magnitude of these 
reductions were similar in both groups, however, modest differences between 
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treatment groups do result in a significant difference in the change in stroke volume 
with dobutamine challenge (Table 14).  Across the range of dobutamine challenge, 
there is a greater reduction in stroke volume of saline treated animals than is found 
in their liraglutide counterparts.  Moreover, the relative decrease in ejection fraction 
found in saline treated animals (~19%) is attenuated in liraglutide treated animals 
(~7%).  This preservation of ejection fraction in liraglutide treated animals is such 
that it is not significant across the range of dobutamine challenge meaning that, 
whereas saline treated animals demonstrate characteristics of heart failure, 
liraglutide treated animals are more aptly characterized as animals demonstrating 
heart failure with preserved ejection fraction. 
While it may seem paradoxical that liraglutide treated swine had increased 
cardiac contractility despite lower expression of β1ADR, the combination has been 
previously observed as conferring benefit in other clinically relevant scenarios. 
Reduction in beta-adrenergic signaling, via beta blockade, is frequently used to 
improve cardiac function including in the setting of heart failure 263. Reducing beta-
receptor signaling disrupts the positive feeback loop (maladaptive adrenergic 
signaling) that pushes the heart towards hypertrophy and eventually failure 264. 
Alternative mechanisms can be employed that improve cardiac mechanical work 
without additional demand for myocardial oxygen uptake including, altering 
calcium handling and contractile machinery 224, and improving nutrient utilization 
214. Prior proteomics studies performed by our laboratory 242 support that exendin-
4, another GLP-1 related therapeutic, changed the expression of key calcium 
handling proteins, components/regulators of sarcomeric proteins, and metabolic 
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proteins. Further research is needed to better define the liraglutide induced 
alterations in calcium handling, contractile apparatus, and nutrient utilization in 
obesity (see next section regarding cardiac efficiency). 
Cardiac Efficiency  
Based on changes between groups in Starling forces at rest and inotropic 
responses with dobutamine challenge, the cardiac efficiency of the system could 
potentially be altered with liraglutide therapy.  Pioneering work by Hiroki Suga has 
demonstrated a linear relationship between pressure volume area and myocardial 
oxygen consumption 248, 265.  Therefore, based on the data obtained with transient 
IVC occlusion in this study, we are able to assess the myocardial oxygen 
consumption within the heart based on the PVA.  Considering that the hearts of 
liraglutide treated animals demonstrate force development at lower pressure when 
at rest, the first question with regard to efficiency is whether myocardial oxygen 
consumption is different between treatment groups at rest.  PVA was found to be 
statistically similar (P = 0.897) indicating that myocardial oxygen consumption is 
similar between treatment groups. Cardiac power (work per unit time) can further 
be calculated as the triple product of stroke volume, aortic pressure and heart rate. 
As was found with PVA, cardiac power was similar between treatment groups at 
rest (P  = 0.084). The relationship between cardiac power (work) and PVA 
(consumption) is an index of cardiac efficiency.  Both groups begin at similar 
efficiency.  However, when data for cardiac power (work per unit time) are 
expressed relative to PVA (Figure 22) we can see that liraglutide fundamentally 
increases the relationship between left ventricular power generated at any level of 
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oxygen consumption beyond baseline relative to saline.  Therefore, although the 
hearts of liraglutide treated animals demonstrate similar Ees, liraglutide treatment 
results in a significant enhancement of cardiac efficiency under conditions of 
enhanced metabolic demand. 
Limitations.  
Owing to the resource-intensive nature of these studies and some animal 
loss with chronic unrelieved left ventricular ischemia/infarction, this study presents 
relatively small group sizes. Nevertheless, we noted statistically significant 
differences in key physiologic end points that were associated with marked 
changes in HR, SV, EF & CO relative to EDV. These observations therefore are 
not compromised on statistical power overall, although one could argue that the 
sample size raises questions of representativeness. In this regard, we did not 
observe individual animals to introduce significant outliers for any of the evaluated 
physiological parameters.  
Post-euthanasia molecular analysis was limited by the need for whole, 
uncompromised hearts for accurate infarct measurement. Formalin fixation and 
staining with tetrazolium chloride prevented use of fresh tissues for gel based 
analysis or ELISA. Formalin fixed tissues were biopsied and used for IHC. To 
minimize bias inherent to histological analysis, we utilized digital pathology 
techniques to quantify stain. 
Conclusions and Implications.  
Taken together, findings from this investigation suggest that 30 day 
liraglutide exposure in obese swine does not reduce infarct size development in 
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the setting of unrelieved ischemia.  As previously stated, this finding is unsurprising 
and the result may differ under conditions of ischemia/reperfusion.  Hearts from 
animals receiving chronic liraglutide treatment were shown to have preserved β 
adrenoreceptor expression with an accompanying preservation of responsiveness 
to dobutamine challenge.  Whereas saline treated animals were largely 
unresponsive to dobutamine, this was not true of liraglutide treated animals.  
Moreover, dobutamine challenge was associated with increasing pressure volume 
area in both treatment groups indicative of enhanced myocardial oxygen 
consumption.  However, this resulted in a near zero outcome in change in cardiac 
power for control animals indicating that under conditions of enhanced sympathetic 
stress, the hearts of control animals will continue to significantly increase 
myocardial oxygen consumption with no benefiting increase in cardiac power.  By 
contrast, the efficiency of liraglutide hearts across a range of dobutamine challenge 
is significantly enhanced owing to enhanced cardiac performance.  Taken 
together, these data support a potential role for liraglutide therapies in maintaining 
sympathetic responsiveness of hearts in obese individuals with chronic ischemic 
heart disease.  
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Chapter 3 Tables and Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Saline Liraglutide P value 
Body Mass (kg) prior to 
ameroid placement 
63 ± 
11 
52 ± 4 0.31 
Body Mass (kg) prior to 
terminal study 
70 ± 6 54 ± 3 0.02 
Delta Body Weight (kg) 9 ± 4 1 ± 2 0.09 
Heart Weight (g) 
223.3 
± 17.5 
218.4 ± 
13.9 
0.85 
Heart Weight /Body 
Weight Ratio 
0.33 ± 
0.04 
0.41 ± 
0.02 
0.09 
Table 12. Phenotype characteristics of obese swine  
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Table 13. Effects of liraglutide therapies on hemodynamic and cardiac 
parameters.  
Baseline 0.3 1 3 10
Saline  93 ± 7 96 ± 9 99 ± 8 104 ± 9 107 ± 10
Liraglutide  95 ± 3 95 ± 1 94 ± 1 98 ± 4 101 ± 7
Saline  64 ± 6 65 ± 6 67 ± 7 67 ± 5 68 ± 6
Liraglutide  64 ± 4 63 ± 3 62 ± 3 63 ± 3 61 ± 4
Saline  77 ± 6 77 ± 7 80 ± 7 81 ± 6 82 ± 7
Liraglutide  77 ± 3 77 ± 2 77 ± 2 78 ± 3 77 ± 4
Heart Rate Saline    77 ± 13 80 ± 14 89 ± 17 116 ± 22   145 ± 17*
(bpm) Liraglutide  106 ± 11 119 ± 14 122 ± 15 144 ± 13 162 ± 16
Saline  100 ± 13 88 ± 11 88 ± 16 74 ± 16 55 ± 11*
Liraglutide  83 ± 8 78 ± 10 74 ± 8 61 ± 5 47 ± 4
Saline    56 ± 14 57 ± 15 59 ± 16 49 ± 11 39 ± 7
Liraglutide  46 ± 5 45 ± 5 43 ± 4 38 ± 4 31 ± 4
SV Saline  44 ± 4 30 ± 4 29 ± 3 25 ± 7 16 ± 5*
(mL) Liraglutide  36 ± 6 33 ± 6 31 ± 6 23 ± 3 17 ± 2*
CO Saline  3298 ± 446 2273 ± 220 2529 ± 444 2854 ± 978 2550 ± 844
(mL) Liraglutide  4594 ± 778 3871 ± 735 3713 ± 734 3310 ± 592 3029 ± 322
Ejection Fraction Saline  48 ± 9 39 ± 10 38 ± 9 36 ± 8 28 ± 6
% Liraglutide  43 ± 4 42 ± 4 40 ± 4 38 ± 4 37 ± 4
CT Saline  53 ± 2 57 ± 4 49 ± 5 43 ± 4 43 ± 4
(msec) Liraglutide  66 ± 8 59 ± 8 55 ± 8  44 ± 4* 37 ± 2*
RT Saline  142 ± 16 104 ± 18* 131 ± 14 113 ± 13 96 ± 9*
(msec) Liraglutide 121 ± 5 120 ± 4 112 ± 4 97 ± 4 83 ± 6*
dPmax Saline   1204 ± 157 1230 ± 170 1548 ± 250 2350 ± 403* 3071 ± 574*
(mmHg/sec) Liraglutide 1599 ± 92 1535 ± 92 1577 ± 162 2271 ± 239 3105 ± 439*
dPmin Saline -858 ± 66 -832 ± 138 -955 ± 193 -1126 ± 235 -1379 ± 178
(mmHg/sec) Liraglutide -1181 ± 122 -1214 ± 111 -1215 ± 130 -1493 ± 128 -1816 ± 263*
Tau 1/2 Saline 32 ± 2 29 ± 3 33 ± 4 30 ± 4 23 ± 2
(msec) Liraglutide 30 ± 3 29 ± 1 28 ± 1 23 ± 1† 18 ± 3*
Tau 1/e Saline 22 ± 2 20 ± 2 23 ± 3 22 ± 3 16 ± 2
(msec) Liraglutide 21 ± 2 20 ± 1 19 ± 1 15 ± 1† 12 ± 2*
P = 0.004
P = 0.05
P = 0.04
Dobutamine
P = 0.38
P = 0.22
P = 0.45
Systolic Pressure 
(mmHg)
Diastolic Pressure 
(mmHg)
Mean Pressure 
(mmHg)
Treatment
P = 0.001
P = 0.03
P = 0.03
End Diastolic 
Volume (mL)
End Systolic 
Volume (mL)
P = 0.74
P = 0.57
P = 0.34
P = 0.40
P = 0.02
P = 0.11
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Table 14. Change in Hemodynamic Parameters presented in Table 13. 
Significantly different changes in Stroke Volume and Ejection Fraction are depicted 
in Figure 19.   
Baseline 0.3 1 3 10
Saline 0 ± 0 3 ± 3 12 ± 8 36 ± 14 67 ± 8
Liraglutide 0 ± 0 28 ± 25 31 ± 26 53 ± 25 48 ± 13
Saline 0 ± 0 -12 ± 4 -13 ± 8 -26 ± 10* -45 ± 9*
Liraglutide 0 ± 0 -5 ± 3 -8 ± 2 -21 ± 6* -35 ± 9*
Saline 0 ± 0 1 ± 1 3 ± 3 -7 ± 4 -17 ± 7*
Liraglutide 0 ± 0 -2 ± 1 -3 ± 2 -8 ± 3 -15 ± 5*
SV Saline 0 ± 0 -14 ± 4 -15 ± 6 -19 ± 10* -28 ± 9*
(mL) Liraglutide 0 ± 0 -3 ± 2 -6 ± 2 -13 ± 4 -20 ± 5*
CO Saline 0 ± 0 -1025 ± 313 -768 ± 253 -444 ± 685 -747 ± 801
(mL) Liraglutide 0 ± 0 -722 ± 346 -880 ± 350 -1284 ± 601 -1564 ± 594
Saline 0 ± 0 -9 ± 2 -10 ± 3 -12 ± 7 -19 ± 11*
Liraglutide 0 ± 0 -2 ± 1 -3 ± 2 -5 ± 2 -7 ± 2†
Saline 0 ± 0 2 ± 1 6 ± 2 4 ± 2 6 ± 3
Liraglutide 0 ± 0 2 ± 1 7 ± 2 9 ± 2 18 ± 7†*
V0 Saline 0 ± 0 12 ± 7 16 ± 4 6 ± 9 0 ± 6
(mL) Liraglutide 0 ± 0 7 ± 3 10 ± 5 12 ± 4 8 ± 3
P = 0.88
P = 0.12
P = 0.18
P = 0.47
P = 0.03
P = 0.32
P = 0.006
End Systolic 
Volume (mL)
Ejection 
Fraction %
ESPVR 
(mmHg/mL)
Dobutamine
Treatment
P = 0.44
Heart Rate 
(bpm)
End Diastolic 
Volume (mL)
Change in:
∆
∆
∆
∆
∆
∆
∆
∆
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Figure 16. Illustration of approximate ameroid closure and liraglutide dosing 
during the duration of the experimental protocol.  
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Figure 17. Representative transmural sections of left ventricle. White 
tissues within the myocardium were not stained, representing infarcted tissue. No 
difference in infarct was detected as a % of total left ventricular area.  
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Figure 18. Panels A and B show representative PV loops from saline treated 
(A) and liraglutide treated (B) swine at baseline (solid) and at 10µg/kg/min 
dobutamine (broken). C) liraglutide treatment was associated with lower V0 (P < 
0.001 for treatment effect). D) Liraglutide treated swine hearts had greater 
contractility relative to untreated swine at the maximum dose of dobutamine, but 
no overall treatment effect was detected (P = 0.377). † = P<0.05 for vs tx at same 
time point ; * = P<0.05 relative to baseline same tx.   
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Figure 19. These graphs show change in stroke volume (A) and ejection 
fraction (B) over the course of the dobutamine challange. Stroke volume 
decreased in both groups. Dobutamine significantly reduced ejection fraction 
saline swine, while liraglutide diminished the reduction. * = P<0.05 dob dose 
relative baseline; † = P< 0.05 tx relative to saline; A. p value for tx = 0.029; B. P 
value for tx = 0.006.   
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Figure 20. When data for each animal are included across all experimental 
time points, liraglutide was associated with greater cardiac output at a given end 
diastolic volume  (P = 0.002 for ANCOVA tx effect).   
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Figure 21. The slope of the relationship between cardiac power and PVA 
was higher in liraglutide treated swine hearts. As PVA provides an index for cardiac 
O2 consumption, we see that liraglutide increased cardiac work at a given level of 
cardiac energetics.  Thus, liraglutide increased cardiac efficiency. P value is 
ANCOVA tx effect. P = 0.02 for homogeneity of regressions.  
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Figure 22. β1ADR expression was reduced in left ventricle of obese swine 
due to liraglutide and ischemia. Images A-D show representative left ventricular 
myocardial staining for β1ADR. A) saline treated, normally perfused, B) liraglutide 
treated, normally perfused, C) saline treated, ischemic, D) liraglutide treated, 
ischemic. † = p<0.05 vs. tx same condition. * =  p<0.05 vs. condition same tx 
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Chapter 4: Discussion and Implications, Future Directions 
Discussion and Implications 
Ample clinical and epidemiological evidence supports that obesity 
increases the risk of development, and severity of cardiovascular disease. 
Additional data is emerging that supports that obesity changes cardiac responses 
to pathologic and pharmacologic stimuli, but they remain poorly 
characterized/understood with regards to both physiology and mechanism. Prior 
work in our lab has revealed that in humans ObM impairs cardiac metabolic 
responses to GLP-1124. Little is known about whether the discrepancy in GLP-1 
effects extend to cardiac function. This work presents data that begins to address 
the aforementioned gaps that remain in literature: 1) does ObM alter cardiac 
functional response to ischemia/reperfusion, 2) are cardiac functional responses 
to I/R altered by GLP-1 mimetics, and are the responses similar in lean and obese 
animals, 3) does obesity modify cardiac microRNA and protein expression to GLP-
1 mimetics and in the setting of I/R, 4) does treatment with GLP-1 mimetics reduce 
infarct in obese animals 5) does GLP-1 produce cardiac functional differences in 
the obese ischemic heart. Questions 1, 2, and 3 were assessed in aim 1 (chapter 
2), while questions 4 and 5 were investigated in aim 2 (chapter 3). 
Aim 1. Determine the effects of obesity on the cardiac functional response 
to ischemia/reperfusion and/or glucagon like peptide-1 (GLP-1) receptor 
activation, and screen for underlying microRNA and protein changes.  
The goal of this work was to elucidate whether obesity alters cardiac 
function, injury and molecular responses to GLP-1 therapeutics in the setting of 
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ischemia. We hypothesized that obesity will alter cardiac functional responses to 
GLP-1 and I/R, and furthermore, that underlying these differences are associated 
changes in miR and protein expression. 
To investigate this aim, lean and obese Ossabaw swine were given 24 
hours of intra-venous saline or exendin-4 (30 fmol/kg/min), a GLP-1 receptor 
agonist. An open chest (thoracotomy) model was used to investigate cardiac 
function at baseline and during acute ischemia-reperfusion. Myocardial biopsies 
were taken at the conclusion of the open chest procedure from both normally 
perfused and ischemia-reperfusion territory of the left ventricle. Protein and total 
RNA were isolated from the samples and used for molecular screens using mass 
spectrometry and miR microarray. 
1) Does ObM alter cardiac functional response to ischemia with 
reperfusion? Chapter 2 (Figure 10 and Figure 11) presents highly sensitive, direct 
measures of left ventricular pressure and volume in lean and obese swine. They 
illustrate that obese and lean swine respond oppositely to I/R. During reperfusion, 
hearts of lean swine tended to reduce cardiac filling and generate lower systolic 
pressures, consistent with myocardial stunning. PV loops of obese swine during 
I/R PV-loops show a right shift (increase in EDV) and ability to maintain LV systolic 
pressure.  
2) Does obesity alter cardiac functional responses to GLP-1 mimetics 
(exendin-4) at baseline and in response to I/R? In addition to showing that 
obesity changes cardiac response to I/R in chapter 2, we also demonstrated that 
obesity alters the effect of exendin-4 on left ventricular function in the setting of I/R 
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(Figure 10 and Figure 11). During reperfusion, exendin-4 treatment was associated 
with elevated left ventricle filling volumes and pressures relative to saline treated 
lean swine. This suggests that exendin-4 is able to use increased diastolic filling 
to increase pressure via a volume-dependent (Frank-Starling) mechanism. 
However, during reperfusion, exendin-4 treatment drove reductions in EDV, 
without diminishing pressure generation (Figure 10) relative to saline treated obese 
swine. This supports that EX-4 increased cardiac contractility (greater pressure 
generation at a given EDV) compared with saline treatment in obese swine. Thus, 
this remarkable set of observations support distinct cardiac functional effects of 
exendin-4 on response to I/R dependent on obesity status. 
3) Does obesity modify cardiac microRNA and protein expression to 
GLP-1 mimetics and in the setting of I/R? Molecular screens were employed to 
assess the overall differences in myocardial miR and protein expression as a 
function of obesity and, importantly, how obesity altered response to the GLP-1 
mimetic exendin-4. Upon conclusion of physiological experiments, the animal was 
sacrificed and left ventricular myocardial biopsies were sampled from the normally 
perfused and I/R territories of each heart. MiR microarray and protein mass 
spectrometry revealed significant obesity associated alterations in expression of 
myocardial miR (Figure 14, Figure 15) and protein expression (Figure 12, Figure 
13) were identified. Overall many more miRs were altered in the myocardium of 
obese groups relative to lean saline normally perfused levels. Importantly, exendin-
4 had nearly exclusive effects on miR expression in obese compared to lean 
organisms. While no individual miR was investigated in further detail, the findings 
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within this work are among the first to demonstrate that miR responses to I/R are 
dependent on metabolic status (obesity), and treatment with therapeutics 
(exendin-4).  
Obesity was also associated with extensive protein expression differences. 
Protein quantification revealed significant differences in nearly every category of 
myocardial cellular physiology, including: metabolism, mitochondrial function, cell 
structure/extracellular matrix/cell adhesion, cell proliferation/survival/death, 
calcium handling (Figure 12), and contractile/motor proteins.  Importantly, the 
abundances of these proteins were differently impacted by exendin-4 in obese vs. 
lean hearts. While this work cannot reveal the mechanisms describing cause or 
consequence of these changes, novel targets emerge for further investigation. For 
example, myocardial titin and calcium handling proteins (Figure 12) provide 
possible, and relatively unexplored targets for investigation of the obesity mediated 
differences in cardiac pathologic and pharmacologic response. 
The importance of these molecular findings should not be dismissed due to 
lack of causal links. The work presented in chapter 2 shows that current efforts to 
investigate the mechanism of GLP-1 and I/R (as well as many related diseases 
and therapeutics) fail to consider that obesity globally changes tissue level genetic 
expression/regulation in response to pathologic and pharmacologic stimuli; these 
molecular changes are associated with concurrent, clinically significant and 
fundamentally distinct cardiac functional responses. 
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Aim 1 Implications 
The findings presented in chapter 2 (aim 1), if found to be true in humans, 
could have considerable implications both for future I/R and GLP-1 related basic 
science research, as well as clinical practice. Investigations seeking to interrogate 
cardiac functional responses to I/R (and related phenomena such as stunning, 
preconditioning, postconditioning), and search for cardioprotective therapeutics 
are typically performed on otherwise healthy organisms120, 266, 267. The data 
presented within chapter 2 demonstrating differential cardiac (physiologic and 
pharmacologic) response due to underlying metabolic disease, implies that 
investigators examining ischemic disease and/or GLP-1 response must take 
underlying metabolic status into account when proposing, designing and 
interpreting “translational” research. Of course, not only overweight/obese people 
have myocardial infarctions and CVD. This begs the question as to whether CVD 
should be approached as the same pathology in lean and obese humans.  
The data within chapter 2 suggests that our current efforts to apply a “one 
size fits all” recipe for producing studies aiming to discover or assess mechanism 
or therapy associated with I/R and cardioprotection are likely dependent on 
underlying metabolic state of the model used. Similarly, differential response to I/R 
may suggest a clinical need for alternative post-MI treatment of lean compared 
with obese humans. For example, as only lean swine groups displayed functional 
cardiac responses suggesting myocardial stunning, are beta blockers (currently 
part of standard post-MI therapy268) of equal utility in lean and obese swine? Would 
beta blockers depress cardiac function further and reduce contractility leading to 
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impaired systemic blood delivery? Additional studies are needed to assess 
outcomes following the differences observed lean vs. obese swine. 
Aim 2. Investigate the potential for GLP-1R activation to influence cardiac 
function at rest and in response to β1-adrenergic receptor (β1ADR) 
stimulation in an obese swine model of ischemic heart disease. 
Ameroid constrictors were placed on the left anterior descending (LAD) 
artery of obese Ossabaw swine in a sterile, open-chest procedure. Ameroid 
constrictors produce a slowly developing (over the course 2 weeks), 
complete/unrelieved coronary occlusion. Following ~30 days of treatment with 
either saline, or the GLP-1 mimetic liraglutide (0.015 mg/kg/day), an open-chest 
procedure was performed in which we assessed whether liraglutide augments 
sympathetic mediated increases in cardiac contractility and improve efficiency of 
obese hearts following complete coronary occlusion and regional myocardial 
infarction. Furthermore, ex vivo investigations elucidate the impact of liraglutide 
treatment on infarct development, β1ADR expression, and titin in the infarcted and 
normally perfused myocardium. 
4) Does treatment with GLP-1 mimetics reduce infarct resulting from 
unrelieved LAD ischemia in obese swine? 
Ameroid constrictors were surgically implanted in obese, age-matched, 
ossabaw swine.  Liraglutide treatment began on the day of the sterile procedure in 
which the ameroids were surgically implanted on the LAD. Thus, as the collagen 
ring in ameroid absorbed water over the course of 2 weeks both the normally 
perfused and ischemic territories were exposed to saline or liraglutide. Following 
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an additional two weeks (during which complete ameroid closure produced 
unrelieved ischemia of LAD perfusion territory), and a dobutamine challenge, 
hearts were stained for infarcted area. Figure 17 in chapter 3 illustrates the results 
of this experiment. Liraglutide did not reduce the volume of infarcted left ventricle 
compared with saline treated animals. This finding is not unexpected as the 
ischemia was both complete and unrelieved. Research reporting cardioprotective 
effects of GLP-1 mimetics often do not utilize models of unrelieved ischemia 120, 
256, 257, 269-272. However, the use of unrelieved ischemia allowed for assessment of 
functional effects of GLP-1 on the normally perfused myocardium. 
5) Does GLP-1 produce cardiac functional differences in the obese 
ischemic heart? Approximately 30 days after ameroid placement pigs were 
anesthetized for an open-chest procedure in which cardiac function was measured 
at baseline and during dobutamine stress test using admittance pressure-volume 
catheter technology. No differences were detected in baseline function. Several 
important differences emerged during dobutamine dose response. Despite 
unchanged infarct volume of the left ventricle, liraglutide treatment increased 
cardiac contractility (Table 13, Figure 20), and improved diastolic function in obese 
swine. Additionally, Figure 21 shows that liraglutide treatment increased cardiac 
efficiency (more work performed at a given level PVA).  As PVA is a metric of 
oxygen consumption214, 273, these changes in cardiac contractility were produced 
independent of O2 consumption. To probe potential involvement of inotropy 
mediated by adrenergic signaling, immunohistochemical analysis of β1ADR 
expression was performed in biopsies of both the normally perfused and infarcted 
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regions of the left ventricle (Figure 22). In the normally perfused territory, liraglutide 
was associated with a significant decrease in in staining for β1ADR. Also, a 
significant reduction in β1ADR staining was detected in infarcted regions of both 
treatment groups. 
Aim 2 Implications 
The findings of the experiments within chapter 2 are particularly 
provocative. These data are the first volume independent measures of contractile 
function during I/R in a large animal model of obesity receiving GLP-1 mimetics. 
They demonstrate that, in obese swine, liraglutide was not able to reduce infarct 
in unrelieved ischemia, but was able to increase efficiency of surviving myocardium 
under sympathomimetic stress. Interestingly, these increases in cardiac 
contractility seem to be independent myocardial β1ADR expression (the receptor 
that mediates the classic inotropic activation of sympathetic activation). These 
important findings contribute to the growing body of knowledge supporting that 
cardiovascular effects of GLP-1 require a stress (ischemia129, 242, adrenergic 
challenge, etc.) to manifest.  
These findings may have significant clinical implications. First, excess 
β1ADR  signaling is a known mediator of cardiac hypertrophy and eventual heart 
failure274 (hence the use of beta blockade in post MI management268, as well as in 
heart failure263). Thus, liraglutide associated reductions in β1ADR expression in 
surviving myocardium may contribute to reduction in cellular signaling promoting 
hypertrophy, decline in cardiac function, and eventual progression towards heart 
failure263, 274 as is common post-MI275. However, our data suggests additional 
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benefit conferred by liraglutide treatment in that independent of adrenergic 
signaling, it increased cardiac diastolic function, contractility and efficiency in the 
setting of pathologies associated with impaired cardiac function. 
Future Directions 
The results of these studies demonstrate novel effects of GLP-1 mimetics 
on cardiac function, gene regulation, and protein expression. The nature of these 
works have generated many questions (Figure 23).  One pressing question that 
emerges when considering the differential effects of GLP-1 on lean and obese 
swine is whether the alterations in cardiovascular function and molecular 
expression observed during reperfusion confer any long term benefit or detriment 
to the recovering heart, as well as to the animal as a whole.  
By combining elements of the protocols used in chapters 2 and 3 
investigation of GLP-1 effects on load-independent cardiac function post-MI can 
be performed. To accomplish this, age matched lean and obese Ossabaw swine 
on diet for 6 months would undergo an initial sterile surgery in which implantation 
of catheters for aortic, jugular central line, and interventricular blood sampling 
cannulas, a Fogerty venous catheter placed in the IVC, as well as telemetry 
(Transonic) devices containing leads for admittance pressure volume catheters, 
coronary flow probes on the LAD and left circumflex artery, and systemic pressure 
would precede baseline recordings, a 30 minute left coronary artery coronary 
occlusion followed by subsequent closure of the surgical site and recovery.  
On the day of surgery, during the 30 minute coronary occlusion, pigs would 
begin receiving once daily injections of either saline or liraglutide for 30 days. As 
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we cannot predict when a person will have a MI, this study is analogous to starting 
a patient on liraglutide when they show up to the hospital with a MI.  Telemetry 
would allow for monitoring of multiple cardiac functional (including load 
independent cardiac contractility), hemodynamic, cardiac metabolic (via arterial vs. 
coronary venous plasma analysis), and circulating miR/hormone measures at 
various time points (even multiple times a day). The use of telemetry would also 
facilitate the addition of exercise or adrenergic stress tests (drug infusion via 
jugular central line) for intermediary functional measures during healing. Cardiac 
catheterization lab procedures would allow sampling of left ventricular tissue via 
endomyocardial biopsy. This tissue could be used for microRNA and protein 
analysis. 
On day 30 swine would be anesthetized for terminal open chest procedure. 
After baseline recordings, a 30 minute circumflex coronary artery ischemic period 
would ensue. Following 2 hours of reperfusion, a final dobutamine challenge (as 
in the methods described in chapter 3). These final steps would provide slightly 
unrelated, but clinically relevant data, shedding light on GLP-1 mimetics’ ability to 
improve cardiac function in patients who remain high risk individuals for additional 
coronary vascular disease after they have already had an MI (similar to 
preconditioning, though this timeline would not be considered “preconditioning” per 
se). The results and whether obesity altered the efficacy would potentially have 
important implications for patients at risk for CVD. Upon sacrifice, LV myocardium 
could also be used for additional analyses including GLP-1 receptor identification 
(described later), and for myocyte dispersions for calcium imaging analysis230, 276. 
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The use of Ossabaw swine would be advantageous in that calcium handling and 
receptor differences in obese vs. lean state could be probed. 
This procedure, while very complex and expensive, would provide much 
needed temporal understanding of functional outcomes associated with GLP-1 
agonism post I/R. Periodic tissue samples would provide a much needed picture 
of how GLP-1 alters miR and protein regulation over time as healing occurs in the 
I/R region, as well as adaptation occurs in the normally perfused region.  
The data in chapter 2 show that molecular response to GLP-1 in the heart 
appear to be highly variable and dependent on physiological/pharmacological 
context. Methodical studies are needed to distinguish cause from effect. As GLP-
1 receptor(s) and localization are not well described, attempting to ascribe 
meaning (causal relationships) to single factors within the multitude of molecular 
changes, then decipher the effect of a single factor on gross functional outcomes 
within a complex/adapting system seems premature. First, there is need for more 
research into the binding partners of GLP-1 and related synthetic therapeutics. In 
order to better characterize binding partners we propose using variants of affinity 
chromatography to discover binding partners. First gentle cell disruption (non-
denaturing and without detergent) and cellular fractionation techniques would 
allow separation of nuclear, mitochondrial, cytosolic and membrane bound 
proteins from swine myocardium. The individual fractions could then be washed 
over biotinylated GLP-1 (Anaspec) (ideally the same experiment would be 
repeated using various GLP-1 mimetics) bound to streptavidin beads, thus 
accomplishing a GLP-1-pulldown. After washing beads, eluting off bound proteins, 
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and performing mass spectrometry for protein identification, the resulting proteins 
identified should, in theory, be capable of binding GLP-1. This protocol would yield 
different results dependent on immobilization techniques and strength of binding 
of GLP-1 and targets. Using a variety of conditions for each cellular fraction should 
yield protein database with putative binding partners of GLP-1 within each fraction. 
An advantage to this approach is that it allows discovery of proteins that can bind 
GLP-1 mimetics in each fraction, thus shedding light into the hypothesized 
intracellular and even nuclear GLP-1 actions277.  
These findings could be confirmed biochemically using surface plasmon 
resonance278. This technique allows for immobilization of one binding partner (a 
recombinant version of predicted GLP-1 binding protein discovered via mass 
spectrometry) to a gold membrane. Lasers are reflected off of the underside of the 
gold foil membrane and reflect into a detector. Using microfluidics predicted GLP-
1 or GLP-1 therapeutics would be washed over the membrane. As GLP-1 moves 
across the foil, events in which GLP-1 binds an immobilized protein produces 
changes in the detected laser light. The changes in detection are related to the 
duration of binding, thus these changes, along with using known concentrations of 
soluble and immobilized target, allow for determination of binding kinetics278. It is 
important to note that surface plasmon resonance has been applied to membrane 
bound proteins278 and could characterize binding kinetics of various membrane 
bound proteins including putative membrane bound receptors.  
Through the date of publication of this work, attempts to define mechanism 
have been convoluted by lack of a piecemeal approach in what appears to be an 
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abandonment of meticulous basic science methodology. Instead, attempts seem 
to favor uncoordinated and experimentally inconsistent approaches to find “THE” 
responsible factor - a sort of ‘Holy Grail’ quest. Often these studies succeed in 
identifying alterations in a “mechanistic component” in the search for translational 
end points (understandably so, as it is a near prerequisite for funding in the current 
climate of research). However, these findings pile up and have resulted in context-
specific (often contradictory) and ultimately non-integrable body of knowledge. 
It is possible that slow and steady science might “win” the translational race. 
Identification of GLP-1 binding proteins would provide insight into putative GLP-1 
mechanisms (Figure 24). Following receptor characterization, systematic 
approaches could be taken to discover the mechanisms of direct cardiac effects of 
GLP-1s. Once the mechanism of action is characterized, hypothesis driven 
investigations of obesity-associated perturbations of the already known 
mechanism could follow. 
  
  122 
Chapter 4 Figures 
Figure 23. Many questions remain in a complex, interrelated system. 
Deciphering the direct cardiac effects of GLP-1 and how they are changed by 
obesity will take systematic and methodical approaches. Several questions are 
highlighted in this figure that are not classically explained by GPCR (i.e the 
canonical GLP-1 receptor) action. Prior investigations by Moberly et al. showed 
that GLP-1 can increase glucose uptake in humans and were associated with 
increased P38 activity. However, the end effector for this increase is still unknown. 
Other questions remain: how does GLP-1 alter regulation of calcium handling and 
contractile proteins (chapter 2 Figure 12). how does miR regulation change over 
time, and how do they modulate disease progression?  Is a second GLP-1 receptor 
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mediating these changes? One key question not represented in this figure is of the 
utmost importance: how does obesity change this system and drug effects? 
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Figure 24. Many target pathways may be involved in GLP-1 effect. 
Characterizing the unknown “second receptor” may allow for clarification of key 
pathways mediating the new effects of GLP-1 highlighted by this work (changes in 
calcium handling proteins, miR regulation, and sarcomeric proteins).  
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